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ABSTRACT OF DISSERTATION 
 
 
 
TUMOR-DERIVED PROTEINS AND MITOCHONDRIAL DYSFUNCTION IN 
LUNG CANCER-INDUCED CACHEXIA 
 
Lung tumors secrete multiple factors that contribute to cachexia, a severe 
wasting syndrome that includes loss of muscle mass, weakness, and fatigue. 
80% of advanced lung cancer patients experience cachexia, which cannot be 
reversed by nutritional interventions, diminishes response to and tolerance of 
cancer treatments, and increases morbidity and mortality. Despite a multitude of 
clinical trials, there are currently no approved treatments. This deficiency 
suggests that not all of the factors that contribute to cachexia have been 
identified. Cancer is frequently accompanied by an increase in cyclooxygenase-2 
(COX-2), a hallmark of inflammation. Clinical trials for COX-2 inhibitors have 
resulted in restoration of muscle mass and decreased fatigue. Along with loss of 
myofibrillar proteins, cachexia also induces mitochondrial dysfunction, which 
contributes to fatigue. The amelioration of fatigue by COX-2 inhibition suggests 
possible alterations to mitochondrial function. We hypothesized that there were 
unidentified tumor-derived factors that contribute to cachectic wasting and 
fatigue. Treatment of C2C12 myotubes with Lewis lung cancer-conditioned 
media (LCM) resulted in increased COX-2 content, myosin loss, and 
mitochondrial dysfunction. Mass spectrometry revealed 158 confirmed proteins in 
LCM. We focused on extracellular 14-3-3 proteins because they bind and 
regulate over 200 known partners. We found that depletion of extracellular 14-3-3 
proteins diminished myosin content. CD13, an aminopeptidase, is the proposed 
receptor for 14-3-3 proteins. Inhibiting aminopeptidases with Bestatin also 
reduced myosin content. LCM treatment decreased basal and ATP-related 
mitochondrial respiration, caused a transient rise in reactive oxygen species 
(ROS), and increased 4-Hydroxynonenal (4-HNE) in both cytosolic and 
mitochondrial fractions of cell lysates. COX-2 inhibition did not spare myosin 
content in LCM-treated myotubes, but did alter mitochondrial respiration and 
cytosolic oxidant levels. Our novel findings show that extracellular 14-3-3 
proteins may act as previously unidentified myokines, signaling via 
aminopeptidases to help maintain muscle mass. We elucidated how LCM alters 
mitochondrial electron flow, and increases oxidative damage by ROS and 4-
HNE. Although successful in clinical trials, COX-2 inhibitors do not appear to 
spare muscle mass by directly working on skeletal muscle, but did alter 
mitochondrial function. 
 
KEYWORDS: cachexia, mitochondria, skeletal muscle, myosin, oxidants, 14-3-3 
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1 
CHAPTER 1 
 
Introduction and Background 
 
1.1 Introduction and Overall hypothesis 
 
Cancer kills nearly 600,000 Americans annually, equating to 
approximately 1500 deaths every day (Society, 2012b). Fifty percent of all cancer 
patients experience cachexia, a severe wasting syndrome that includes loss of 
muscle mass, weakness, and fatigue (Tan and Fearon, 2008; Fearon et al., 
2011). Cachexia is unresponsive to nutritional interventions, and limits the 
response to and tolerance of cancer treatments (Fearon et al., 2013). Although 
not all malignancies cause muscle wasting, some types almost inevitably do. 
Eighty percent of patients with advanced lung, prostate, colon, and pancreatic 
cancers present with cachexia (Tisdale, 2009; von Haehling et al., 2010; Fearon 
et al., 2011; Johns et al., 2013). Of these cancers, lung cancer accounts for the 
most deaths in the United States and worldwide (Jemal et al., 2011; Society, 
2012a). This dissertation focuses on lung cancer because 1) it kills more people 
each year than prostate, pancreatic, breast, and colon cancers combined, and 2) 
at the time of diagnosis, 60% of lung cancer patients are already cachectic 
(Society, 2012a; Chacon-Cabrera et al., 2014).  
We have known for more than 150 years that cancer is an inflammatory 
disease. It was 1863 when Rudolph Virchow first documented the observation 
that neoplastic tissues were frequently located at sites of chronic inflammation, 
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and recent clinical trials suggest that cancer cachexia is also related to 
inflammation (Mantovani et al., 2010; Mantovani et al., 2013). Over the last 
several decades, research has revealed the complex and multifactorial nature of 
cachexia (Tan and Fearon, 2008; Blum et al., 2011; Fearon et al., 2011; Tsoli 
and Robertson, 2013). Both the tumor and host tissues are sources for numerous 
inflammatory factors, including Cyclooxygenase-2 (COX-2), Interleukin-6 (IL-6), 
Interleukin 1-beta (IL-1β), Tumor necrosis factor-alpha (TNFα), Monocyte 
chemoattractant protein-1 (MCP-1), and others. These tumor- and host-derived 
inflammatory factors stimulate degradation of myofibrillar proteins via multiple 
signaling pathways, including up-regulation of ubiquitin proteasome activity and 
autophagy (Romanello and Sandri, 2010; Fearon et al., 2013). In addition to 
increased protein degradation, protein synthesis is also reduced, contributing to a 
net loss of muscle mass (Gordon et al., 2013). Recent studies have also noted 
mitochondrial dysfunction, which may account for cachexia-related fatigue 
(Julienne et al., 2012; Fontes-Oliveira et al., 2013; Antunes et al., 2014). While 
the canonical intracellular pathways leading to muscle wasting have been widely 
studied, we know less about how tumor-derived extracellular factors and 
inflammation-related mitochondrial dysfunction alter the balance between protein 
synthesis and degradation.  
This dissertation tests the hypothesis that tumor-derived factors contribute 
to muscle wasting and mitochondrial dysfunction in cancer cachexia. 
 
 
 
 
	  
 
	  
3 
1.2 General background  
 
1.2.1 Skeletal muscle: physiologic functions and pathology  
 
Most of the canonical functions of skeletal muscle have been long known, 
and many can be inferred by anatomical study. Skeletal muscle produces 
movement, maintains bodily posture and temperature, shields internal tissues, 
supports external openings, regulates glucose, and stores nutrients. By the 
1950’s, A.F. Huxley was building the foundations for the sliding-filament theory, 
which postulates the mechanism for muscle contraction (Huxley and 
Niedergerke, 1954). Today, we know many of the biochemical and 
biomechanical details of muscle contraction; however, we are still investigating 
additional functions. It has recently come to light that skeletal muscle serves as 
an endocrine organ, producing paracrine factors that “cross-talk” with other 
tissues to create complex signaling interactions (Pedersen, 2009; Trayhurn et al., 
2011; Pillon et al., 2013). With so many diverse and vital functions, it is no 
wonder that abnormal loss of skeletal muscle has devastating consequences.  
Pathological states that impair skeletal muscle development, repair, or 
maintenance may be caused by genetic defects or by aberrant signaling. Many 
diseases elicit muscle wasting through aberrant signaling: malignant tumors, 
chronic obstructive pulmonary disease, sepsis, renal failure, chronic heart failure, 
inflammatory myopathies, and some autoimmune disorders disrupt the canonical 
signaling pathways that regulate muscle mass. Loss of muscle mass in some 
pathologies, including cachexia, includes preferential loss of the major contractile 
 
 
	  
 
	  
4 
protein, myosin (Pickering et al., 2002; Tisdale, 2005; Banduseela et al., 2007; 
Johns et al., 2013). Muscle wasting then results in weakness, fatigue, respiratory 
complications, and increased morbidity and mortality.  
 
1.2.2 Anatomy of skeletal muscle: cellular level  
Skeletal muscle comprises up to 50% of body weight. Muscle fibers are 
cylindrical, multinucleated cells composed of actin and myosin myofibrils that 
repeat in discrete units called sarcomeres (Figure 1.3); (Hill, 2012). Myosin 
accounts for up 50% of total protein content in skeletal muscle, and is the major 
player in muscle contraction (Hill, 2012). During contraction, myosin and actin 
filaments slide over one another in a calcium- and ATP- dependent process 
known as cross-bridge cycling, which leads to the production of force and 
movement. Mitochondria, embedded between myofibrils, and under the 
sarcolemma, supply much of the ATP for cross-bridge cycling. 
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Figure 1.1 Schematic of the structure of a skeletal muscle fiber. This figure 
shows mitochondria between myofibrils and under the sarcolemma, the 
peripheral location of nuclei, and the bundling of myofibrils. Adapted	   from	   the	  
Blauson	  gallery	  (staff,	  2014). 
 
  
1.2.3 Mitochondrial functions in skeletal muscle 
Mitochondria are multi-functional organelles that provide the bulk of ATP in 
most cells, are a major source of reactive oxygen species (ROS), and are 
important to multiple signaling cascades. They also participate in thermogenesis, 
redox balance, and apoptosis. During maximal contraction, ATP consumption in 
skeletal muscle can increase by 100-fold, which likely explains the necessity for 
the dense population of mitochondria in some muscle fibers (Porter and Wall, 
2012). Mitochondria also exhibit plasticity, adapting to cellular dynamics via 
 
 
	  
 
	  
6 
biogenesis, fusion, fission, and autophagy, which is demonstrated by the 
observation that consistent endurance exercise increases mitochondrial 
biogenesis (Peterson et al., 2012).  
Mitochondria catabolize substrates to create ATP in the Krebs cycle and the 
electron transport chain (ETC). The ETC accepts electrons from either NADH or 
FADH2, and moves the electrons through four complexes in the inner 
mitochondrial membrane (IMM) to their final receptor, molecular oxygen, to 
generate water (Figure 1.4). As the electrons are carried through the IMM, 
hydrogen ions are pumped across the membrane to create a proton gradient that 
will ultimately drive ATP synthesis via the fifth mitochondria complex, ATP 
synthase. Electrons that escape the ETC form reactive oxygen species, which 
are vital to some cellular signaling pathways, but in excess may also be 
detrimental to DNA, lipids, and proteins. Likewise, some hydrogen ions may 
cross the IMM without passing through ATP synthase, thereby leading to use of 
oxygen in a manner not linked to ATP production (Peterson et al., 2012). Such 
respiration is said to be uncoupled. 
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Figure 1.2 Depiction of the mitochondrial electron transport chain. NADH 
donates electrons to complex I, which passes electrons through the inner 
mitochondrial membrane via ubiquinone (UQ). Electrons are transported from 
complexes I, III, and IV to the final receptor, oxygen, to generate water. Protons 
are simultaneously pumped through complexes I, III, and IV to create a proton 
gradient with is used by ATP synthase to produce ATP. Figure 4.2 from 
Bioenergetics, 4th edition (Ferguson, 2013). 
 
1.2.4 Signal transduction leading to myosin degradation 
 
Skeletal muscle maintenance is a balance between protein synthesis and 
protein degradation. Increased secretion of inflammatory cytokines, 
glucocorticoids, and inhibitory proteins, such as myostatin and activin A, all lead 
to an imbalance in muscle mass regulation (Figure 1.5). A common feature of 
pathways leading to muscle degradation is increased transcription of the E3 
ubiquitin ligases, MuRF1 and atrogin-1, which ubiquitinate myosin and other 
myofibrillar proteins, marking them for proteolysis (Figure 1.5). Translocation of 
the signaling protein, FOXO, to the nucleus regulates MuRF1 and atrogin-1 
transcription. FOXO translocation is mediated in two parts: 1) by phosphorylation 
 
 
	  
 
	  
8 
by protein kinase B (also known as AKT), and 2) obstruction of its nuclear import 
site simultaneously with exposure of it nuclear export site by an isoform of 14-3-3 
proteins.  
 
 
Figure 1.3 Overview of main pathways of muscle synthesis and 
degradation. The green arrows show pathways activated to promote protein 
synthesis by the IGF-1/AKT/mTOR axis. The green lines ending with bars 
indicate signaling that is inhibited during growth. The red arrows indicate 
pathways activated during cachexia leading to protein degradation through 
increased transcription of MAFbx (aka atrogin-1) and MuRF1. (Johns et al., 
2013). 
 
14-3-3 proteins are a multi-functional and highly conserved family of binding 
proteins with over 200 known partners (Freeman and Morrison, 2011; Gardino 
and Yaffe, 2011; Kleppe et al., 2011; Obsil, 2011). The seven isoforms of 14-3-3 
proteins are typically found in the intracellular environment where they influence 
multiple signaling pathways by altering enzymatic activity, protein-to-protein 
 
 
	  
 
	  
9 
interactions, cellular location, and protein stability (Freeman and Morrison, 2011; 
Gardino and Yaffe, 2011; Kleppe et al., 2011; Obsil, 2011; Tzivion et al., 2011). 
In skeletal muscle, 14-3-3 proteins participate in the regulation of muscle growth 
through interactions with REDD2, as well as muscle degradation through 
interactions with FOXO (Miyazaki and Esser, 2009; Tzivion et al., 2011; Sun et 
al., 2012). Changes in the function or content of 14-3-3 are likely to have a 
substantial impact on signaling pathways. In cardiac muscle, for example, 
depletion of 14-3-3 proteins has been found to increase production of 
inflammatory cytokines as well as ROS, events that are also seen in cachectic 
skeletal muscle (Thandavarayan et al., 2011). Some malignant tumors, including 
lung cancer, alter the content of certain 14-3-3 isoforms, which may contribute to 
increased inflammation in the surrounding tissues, including skeletal muscle 
(Wilker and Yaffe, 2004; Hermeking, 2006; Muhlmann et al., 2010; Freeman and 
Morrison, 2011; Ko et al., 2014). However, whether alterations to 14-3-3 proteins 
participate in cachectic muscle wasting is unknown. 
 
1.2.5 Cyclooxygenase-2 in skeletal muscle 
Cyclooxygenase-2 (COX-2) is an enzyme involved in inflammatory 
pathways. It is both induced by pro-inflammatory cytokines as well as induces 
production of pro-inflammatory cytokines in circuitous manner (Hernanz et al., 
2014). Under physiological conditions, products of COX-2 activity are necessary 
for regulating muscle growth, renal physiology, gastric mucosa, and the acute 
inflammatory response to injury. In excess, prostanoids are mediators of chronic 
 
 
	  
 
	  
10 
inflammation, and have been linked to cancer and cardiac disease (Ricciotti and 
FitzGerald, 2011; Trappe and Liu, 2013). In fact, up-regulation of COX2 is a 
linchpin of tumorigenesis: it is increased in both malignant tumors and in 
cachectic skeletal muscle (Hida et al., 1998; Balkwill and Mantovani, 2001; 
Mantovani et al., 2008; Balkwill and Mantovani, 2010).  
Selective COX-2 inhibitors, such as celecoxib, have had moderate success 
in treating cachexia in clinical trials (Baumgarten et al., 2007; Mantovani et al., 
2010). There are multiple mechanisms by which COX-2 inhibitors could restore 
muscle mass, including decreasing production of cachectic cytokines, such as 
TNF-α and IL-6, which are elevated in the sera of cancer patients (Baumgarten et 
al., 2007; Mantovani et al., 2010). It is important to note that clinical trials for 
other one-target inhibitors, such as TNF-α, have proven ineffective (Mantovani et 
al., 2010). Importantly, people who take COX-2 inhibitors are also less likely to 
develop certain types of tumors (Takada et al., 2004; Backhus et al., 2006; Inoue 
and Aramaki, 2007; Ali et al., 2010; Peulen et al., 2013; Zhang et al., 2013; 
Zhang et al., 2014). This makes COX-2 inhibition an appealing strategy because 
it has beneficial results in skeletal muscle while also working in opposition to 
tumor-growth, a relationship that must be considered for cachexia therapeutics. 
Along with muscle restoration, clinical trials for COX2 inhibitors also noted 
decreased fatigue in some patients (Mantovani et al., 2010). No mechanism was 
suggested, but these results hint that COX-2 inhibitors may affect mitochondrial 
function, a point that we address in this project. 
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1.3 Scope of this thesis 
 
Although cachexia affects 50% of all cancer patients, there are currently no 
effective treatments. Malignant tumors, including lung cancer, secrete paracrine 
factors that alter their environment, and these same tumor-derived factors may 
be responsible for cachexia. The canonical pathways which result in loss of 
muscle mass have been established. However, few tumor-derived mediators that 
may be targets for intervention have been identified. The multifactorial nature of 
cachexia indicates that numerous factors may work in concert to cause muscle 
wasting; therefore, successful treatments will likely be multi-targeted. Identifying 
more of these factors is imperative for developing therapeutics.  
Along with loss of myosin, mitochondrial dysfunction in skeletal muscle may 
be contributing to fatigue: studies that examine mitochondrial function in 
cachectic muscle are scarce. Up-regulation of COX-2, a hallmark of 
inflammation, frequently accompanies cancer. Clinical trials for COX-2 inhibitors 
have resulted in restoration of muscle mass and decreased fatigue, although the 
mechanism is unknown.  
The overall hypothesis of this thesis was that there are tumor-derived 
factors that contribute to cachectic muscle wasting and mitochondrial 
dysfunction. 
In Chapter 2, our goal was to discover potential new targets for cachexia 
therapeutics. We analyzed and identified the tumor-derived protein contents of 
lung cancer conditioned media (LCM). Using databases and a literature review, 
we narrowed down our list to a few proteins of interest. We confirmed their 
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presence and tested their effect on skeletal muscle myosin content in C2C12 
myotubes. 
In Chapter 3, we examine the effect of LCM on mitochondrial function in 
myotubes. We measured oxygen consumption rate, mitochondria complex 
content, complex IV activity, and oxidative stress to assess how LCM affects 
mitochondrial function.  
In Chapter 4, the goal was to determine how COX-2 inhibition restores 
muscle mass and relieves fatigue. We examined the effect of COX-2 inhibition on 
tumor cells or LCM-treated myotubes on myosin content. We also examined 
mitochondrial oxygen consumption, membrane potential, and ROS production in 
myotubes treated with LCM with or without a COX-2 inhibitor. 
Our novel findings revealed previously unidentified myokines, which 
contribute to the maintenance of skeletal muscle mass. We elucidated how LCM 
alters mitochondrial electron flow and oxidative stress. We also discovered novel 
effects of COX-2 inhibitors on mitochondrial function that may alleviate cachexia-
induced fatigue. 
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CHAPTER 2 
 
Proteomic analysis of media from lung cancer cells reveals role of 14-3-3 
proteins in cachexia 
 
2.1 Introduction 
Malignant tumors secrete paracrine factors that alter their environment, and 
these same tumor-derived factors cause muscle wasting. Few of these tumor-
derived mediators that represent potential targets for intervention have been 
identified. As such, there are currently no approved treatments for cachexia, 
although numerous clinical trials have been conducted. Although cachectic 
cytokines are elevated in the sera of cancer patients, clinical trials with one-target 
inhibitors have proven ineffective (Tazi and Errihani, 2010; Mantovani et al., 
2013; Tsoli and Robertson, 2013). For example, a clinical trial to treat cachexia in 
advanced pancreatic cancer patients using the anti-TNFα antibody, infliximab, 
showed no improvement compared to the placebo (Tazi and Errihani, 2010). 
Other clinical trials testing dietary supplements, such as eicosapentaenoic acid 
and melatonin, as well as those testing ubiquitin proteasome inhibitors, have also 
produced with disappointing outcomes (Tazi and Errihani, 2010). These results 
confirm that no single agent is responsible for cachexia, and suggest that there 
may be unknown tumor-derived factors contributing to cancer-induced muscle 
wasting. Identifying more targets may help develop useful therapeutics.  
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We have found that lung cancer-conditioned media (LCM) decreased size 
and myosin content of C2C12 myotubes. C2C12 myotubes, an immortalized 
murine cell line, served as our muscle model because we can study direct effects 
on skeletal muscle under controlled conditions. LL/2 murine lung cancer cells 
served as our cancer model because they are similar to non-small cell lung 
cancer, the most common form of human lung cancer (Society, 2012b). In this 
study, we examined the contents of lung cancer conditioned media using mass 
spectrometry. We confirmed 158 proteins in three biological replicates, and used 
database searches to determine the potential functions of these proteins in our 
model.  
We focused on secreted proteins because they can directly interact with 
skeletal muscle. We identified and tested candidates that we believed might 
contribute to cachexia, and discovered that extracellular 14-3-3 proteins play a 
role in regulating skeletal muscle. 
 
2.2 Materials and methods 
2.2.1 Myotubes 
We plated C2C12 myoblasts (American Type Culture Collection) at a density of 
10,000 cells/cm2 in growth medium {Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% fetal bovine serum (FBS), 1.6 g/L NaHCO3, and 100U/ml 
PenStrep (Invitrogen)}, and grew cells at 37°C in 5% CO2.  After 3 days, cells 
reached ~90% confluence, and we serum-restricted the cells in differentiation 
media (DMEM as above with 2% horse serum replacing FBS). After 4 days in 
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differentiation media, multinucleated myotubes were ready for treatment. Fresh 
medium was added every 2 days (Moylan et al., 2014). 
 
2.2.2 Cancer cells  
Lewis lung carcinoma cells (LL/2: American Type Culture Collection) were 
seeded in 100mm cell culture plates in growth medium (as above) at a density of 
6000 cells/cm2. After two days, we added supplementary growth media to each 
plate. LL/2 cells contain a heterogeneous mix of adherent and floating cells. After 
four days, we removed growth medium, and floating cells were harvested by 
centrifugation at 500xg, 5 min. Pelleted cells and 10mL differentiation media 
were added back to the plate containing the adherent cells. After two days, 
conditioned media were harvested and cleared of cells and debris by 
centrifugation (500xg, 5 min). Aliquots were frozen in liquid nitrogen for later use. 
For myotube treatments, conditioned media were diluted 1 in 4 with fresh 
differentiation media. For mass spectrometry analysis, serum-free media 
replaced differentiation media (McLean et al., 2014). 
 
2.2.3 Western blot 
We homogenized C2C12 myotubes in 2X protein loading buffer (120 mM Tris pH 
7.5, 4% SDS, 200 mM DTT, 20% glycerol, 0.002% bromphenol blue). Proteins 
were separated in equal volumes of lysates by SDS-PAGE (4-15% Criterion, 
BioRad). We determined relative total protein by scanning (Odyssey Infrared 
Imaging, LI-COR) stained gels (Simply Blue, Invitrogen). We used fluorescence 
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intensity data to normalize total protein for equal loading. SDS-PAGE was used 
to separate equal amounts of protein, which was then transferred to PVDF 
membranes for western blot using the Odyssey System (Moylan et al., 2014). For 
conditioned media samples, we combined 6X loading buffer (as above) 1:10 with 
conditioned media, and followed the same procedure as for lysates. 
 
2.2.4 Antibodies 
For western blot, primary antibodies were mouse anti-myosin (Sigma), rabbit 
anti-pan 14-3-3 (Cell Signaling), and rabbit anti-CD13 (Abcam). Secondary 
antibodies included anti-mouse IRDye 800CW and anti-rabbit IRDye 800CW (LI-
COR).  For antibody neutralization experiments, we treated cell culture medium 
with a 1:200 dilution of the primary antibody for pan-14-3-3 or CD13, or the 
respective heat-inactivated control for 48hr.  
 
2.2.5 Fluorescence microscopy and width measurements  
For width measurements, we incubated C2C12 myotubes with nucleic acid stain, 
Syto13 (2.5µM, Invitrogen) for 15 minutes. We captured live-cell bright field and 
fluorescence images (excitation: 488 nm, emission 509 nm) using a CCD camera 
(CoolSNAP-ES, Roper Scientific Photometrics) attached to a Nikon TE2000 
microscope with NIS Elements image acquisition software (Nikon). To obtain the 
average myotube width per well, we measured 3 images per well, 5 myotubes 
per image, and 5 width measurements per myotube. For CD13 
immunofluorescence, myotubes were fixed in 100% methanol cooled to -20C for 
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5 minutes, after which they were blocked for 30 minutes with Odyssey block 
buffer (LI-COR). After blocking, we incubated cells with 1:250 dilution of rabbit 
anti-CD13 antibody (Abcam) overnight at 4C. After rinsing myotubes 3x, we 
incubated myotubes 1hr with 1:1000 secondary antibody, donkey anti-rabbit 649 
(DyLight). We captured fluorescence images using the same system as above 
(excitation: 655 nm, emission 670 nm). Fluorescence was measured with ImageJ 
(NIH).  
 
2.2.6 Proteomics 
Mass spectrometric analysis was performed at the University of Kentucky, 
Proteomics Core Facility. “Acetone precipitation: One milliliter of conditioned 
medium was reduced in volume by vacuum centrifugation to a final volume of 30 
ul.  Three additions of cold acetone, 60 ul each, were made while vortexing the 
sample, and the sample was allowed to sit at -20 C overnight.  Precipitate was 
collected by centrifugation at 12,000 x g for 20 m, supernatant was removed and 
the pellet was allowed to air dry for 20 m. First digestion: 3.3 ug of trypsin (Sigma 
T 6567, St. Louis, MO) was added to the pellet in 40 mM ammonium 
bicarbonate, and the sample was incubated at 37 C for four hours with shaking. 
Reduction and alkylation: The sample was reduced in 10 mM dithiothreitol for 30 
m at 56 C.  This was followed by alkylation by 50 mM iodoacetamide in the dark 
at room temperature for 30 m. Second digestion: Four micrograms of trypsin was 
added for an overnight (18 h) digestion at 37 C.  Upon completion of digestion, 
one microliter of 95% HCOOH was added and sample volume reduced by 
vacuum centrifugation to 30 ul for LC MS/MS analysis. Liquid chromatography-
electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) Analysis: 
Peptides were injected for nano-LC-MS/MS analysis. LC-MS/MS analysis was 
performed using an LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific, 
Waltham, MA) coupled with an Eksigent Nanoflex cHiPLC™ system (Eksigent , 
Dublin, CA) through a nano-electrospray ionization source. The peptide samples 
were separated with a reversed phase cHiPLC column (75 μm x 150 mm) at a 
flow rate of 300 nL/min. Mobile phase A was water with 0.1% (v/v) formic acid 
while B was acetonitrile with 0.1% (v/v) formic acid. A 50 min gradient condition 
was applied: initial 3% mobile phase B was increased linearly to 50% in 24 min 
and further to 85% and 95% for 5 min each before it was decreased to 3% and 
re-equilibrated. The mass analysis method consisted of one segment with eight 
scan events. The 1st scan event was an Orbitrap MS scan (100−1600 m/z) with 
60,000 resolution for parent ions followed by data dependent MS/MS for 
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fragmentation of the 7 most intense ions with collision induced dissociation (CID) 
method.  MS/MS Protein Identification: The LC-MS/MS data were submitted to a 
local Mascot server for MS/MS protein identification via Proteome Discoverer 
(version 1.3, Thermo Fisher Scientific, Waltham, MA) against the human 
component of the Uniprot database. Parameters used in the MASCOT MS/MS 
ion search were: trypsin digest with maximum of two miscleavages, cysteine 
carbamidomethylation, methionine oxidation, a maximum of 10 ppm MS error 
tolerance, and a maximum of 0.8 Da MS/MS error tolerance.  A decoy database 
was built and searched. Filter settings that determine false discovery rates (FDR) 
are used to distribute the confidence indicators for the peptide matches. Peptide 
matches that pass the filter associated with the strict FDR (with target setting of 
0.01) are assigned as high confidence. For MS/MS ion search, proteins with two 
or more high confidence peptides were considered unambiguous identifications 
without manual inspection. Proteins identified with one high confidence peptide 
were manually inspected and confirmed.” We identified locations of the each 
protein during its documented terminal function by database searches in Protein 
(NCBI) and UniProt (UniProt Consortium).  
 
2.2.7 Statistics 
Prism 5.0b served as our statistics software (GraphPad Software).  We 
used ANOVA, or repeated measures ANOVA, with Bonferroni post-test for 
multiple comparisons, and t-test for all other comparisons. Data are presented as 
mean +/- SE. Statistical significance was defined as p<0.05. 
 
2.3 Results 
2.3.1 LCM treatment induces loss of myotube width 
To confirm that our in vitro muscle wasting model decreased myotube size, 
we treated C2C12 myotubes with LCM and measured myotube width. We 
measured width before treatment and found that there was no difference in 
average width between groups. After 48hrs of LCM treatment, we found that the 
average width in control myotubes increased, while the average width in LCM-
treated myotubes decreased (Figure 2.1 A-C). 
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Figure 2.1 LCM-induced loss of myotube width. A) Image of untreated 
myotubes. B) Image of myotubes treated with LCM for 48hrs. C) Graph of 
width changes in control and LCM-treated myotubes (mean ±SE, n=6, 
repeated measures ANOVA, *P<0.05).  
 
2.3.2 LCM treatment decreases total protein and myosin protein content 
Cancer cachexia is known to preferentially degrade the myofibrillar protein, 
myosin (Acharyya et al., 2004; Banduseela et al., 2007; Ochala and Larsson, 
2008). To confirm this outcome in our model, we treated myotubes for 48hr with 
LCM and measured total protein using a protein stain, Simply Blue (LICOR). 
Myosin content was measured with western blot. Compared to control, LCM 
treatment caused a loss of total protein and myosin (Figure 2.2 A-B). 
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Figure 2.2 LCM treatment decreases total protein and myosin in 
C2C12 myotubes. 48hr of LCM treatment decreased A) total protein by 
14%, and B) myosin content by 70% (mean ±SE n=6, P*<0.05, t-test).  
 
2.3.3 Proteins in Lewis lung cancer conditioned media  
Cancerous tumors secrete factors that alter their surrounding environment. 
To investigate which tumor-derived proteins may contribute to myosin loss, we 
used mass spectrometry to examine three biological replicates of serum-free 
LCM. Mass spectrometry identified 446 total proteins, with 158 confirmed in all 
replicates (Figure 2.3A; see Appendix 2 for the full list of proteins). We identified 
the cellular location of the 158 confirmed proteins and found that 33 were 
secreted (Figure 2.3B, see Appendix 3 for the list of putative secreted proteins). 
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Figure 2.3 Mass spectrometry results comparing protein distribution in 
LCM. A) Each circle represents one biological replicate of LCM and compares 
the number of proteins that the replicates shared in common. B) Cellular location 
of the 158 proteins confirmed in LCM. 
 
2.3.4 Extracellular 14-3-3 proteins in LCM and their effect on myosin content 
Our proteomics data showed that LCM contains all seven isoforms of 14-3-3 
proteins, but any effect of extracellular 14-3-3 proteins on skeletal muscle was 
unknown. Using an anti-pan14-3-3 antibody, we assessed 14-3-3 content in 
media conditioned with untreated C2C12 myotubes (C2C12-CM) and in LCM via 
western blot. Compared to C2C12-CM, LCM contained less 14-3-3 content, 
which was unexpected (Figure 2.4A). To assess whether extracellular 14-3-3 
proteins affect myosin content in skeletal muscle, we mimicked the depletion 
seen in LCM by neutralizing 14-3-3 proteins in myotube culture medium using an 
anti-pan14-3-3 antibody. After 24hr, we examined myosin content via western 
blot. Neutralizing extracellular 14-3-3 proteins decreased myosin content 
compared to control myotubes, and myotubes treated with heat-inactivated anti-
pan14-3-3 antibody (Figure 2.4B). 
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Figure 2.4 14-3-3 content and its effect on myosin.  A) Pan 14-3-3 content in 
C2C12-CM versus LCM (mean ±SE n=4, P*<0.05, t-test). B) Myosin content 
decreased when extracellular 14-3-3 proteins were neutralized in myotube cell 
culture medium using an anti-pan14-3-3 antibody (mean ±SE, n=4, *P<0.05, 
ANOVA with Bonferroni post test).  
 
2.3.5 CD13 receptor on C2C12 myotubes and adult skeletal muscle  
CD13 is the proposed receptor for some extracellular isoforms of 14-3-3, 
which given the results in Figure 2.4, may affect myosin content (Ghaffari et al., 
2010). CD13 is found on stem cells, including myoblasts, but its presence on 
differentiated skeletal muscle was not known (Ghosh et al., 2014; Rahman et al., 
2014a; Rahman et al., 2014b). Using an anti-CD13 antibody, we examined non-
permeabilized C2C12 myotubes for CD13 with a fluorescence microscope, and 
found it present (Figure 2.5A). We also confirmed CD13 content in myotubes via 
western blot. We found that LCM-treated myotubes had higher CD13 content 
compared to control (Figure 2.5B). Some pathologies show an increase in a 
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soluble form of CD13 in plasma (van Hensbergen et al., 2002; Piedfer et al., 
2011; Wickstrom et al., 2011). Therefore, we tested CD13 content in C2C12-CM 
versus LCM via western blot and found that LCM contained higher CD13 content 
(Figure 2.5C). 
 
Figure 2.5 CD13 content is elevated in LCM-treated C2C12 myotubes and 
LCM. A) Image of anti-CD13 antibody using a fluorescence microscope. B) CD13 
content in control versus LCM-treated myotubes via western blot (mean ±SE, 
n=6, *P<0.05, t-test). C) Soluble CD13 content in C2C12-CM versus LCM (mean 
±SE, n=4, *P<0.05, t-test). 
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2.3.6 Aminopeptidase inhibitor decreases myosin content in C2C12 myotubes  
Inhibiting the proposed receptor for extracellular 14-3-3 proteins should have 
the same effect on myotubes as neutralizing 14-3-3 proteins. We treated 
myotubes with Bestatin, an inhibitor that blocks the aminopeptidase function of 
CD13 (aka aminopeptidase N), aminopeptidase B, and leukotriene A4 hydrolase, 
which catalyze the cleavage of amino terminus amino acids from protein (N-
terminus) or peptide substrates. Using western blot, we found that 25µM Bestatin 
decreased myosin content (Figure 2.6A). We also used an anti-CD13 antibody in 
myotube culture medium to neutralize CD13, but it did not affect myosin content 
(Figure 2.6B).  
 
Figure 2.6 Inhibition of CD13 with Bestatin, but not antibody neutralization, 
decreased myosin content in myotubes. A) Western blot comparing myosin 
content in control versus Bestatin-treated myotubes (mean ±SE, n=7, *P<0.05, t-
test). B) Western blot comparing myosin content in control myotubes versus 
myotubes for which CD13 was neutralized in myotube culture medium or heat-
inactivated CD23 antibody control (mean ±SE, n=3, n.s., ANOVA). 
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2.4 Discussion 
Cachexia presents in 50% of all cancer patients and contributes to 30% of 
all cancer deaths (Fox and Wang, 2007; Fearon, 2008; Tisdale, 2009). Efforts to 
identify the extracellular factors that initiate cachexia are ongoing. The current 
consensus is that cachexia syndrome is caused by multiple factors (Fearon et al., 
2011; Tsoli and Robertson, 2013). Several well-established cachectic cytokines 
are elevated in the sera of cancer patients, including TNF-α, IL-6, and myostatin 
(Barton, 2001; Jespersen et al., 2006; Kayacan et al., 2006; Gueta et al., 2010; 
White et al., 2013; Lokireddy et al., 2015). However, clinical trials for single-target 
inhibitors fail to fully alleviate muscle wasting (Mantovani et al., 2013; Tsoli and 
Robertson, 2013). These results suggest that unidentified factors may also be 
involved. Our goal was to identify new candidates that may contribute to muscle 
wasting. Our novel findings also show that: extracellular 14-3-3 proteins have a 
role in muscle maintenance, and that CD13 is present on differentiated 
myotubes. Whether CD13 acts as the receptor for 14-3-3 proteins remains 
uncertain.  
 
2.4.1 Model validation and proteomics results 
We began by validating our model using myotube size as a morphological 
endpoint, and myosin as the molecular endpoint. Myosin was chosen because it 
is preferentially degraded in cachexia, and as the major contractile protein in 
skeletal muscle, its loss can depress respiratory function, diminish strength, and 
increase fatigue (Acharyya et al., 2004; Du et al., 2004; Li et al., 2005; Tisdale, 
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2005; Zhang et al., 2011; Johns et al., 2013; Chacon-Cabrera et al., 2014). We 
confirmed that LCM treatment reduced size, total protein, and myosin content in 
myotubes (Figures 2.1 and 2.2). After establishing our model, we began 
identifying proteins in LCM.  
Using mass spectrometry, we confirmed 158 proteins, including 33 secreted 
proteins (Figure 2.3A-B). Some of the proteins identified derived from intracellular 
compartments, a common occurrence in proteomic studies using conditioned 
media (Huang et al., 2006; Kim et al., 2008; Sardana et al., 2008; Planque et al., 
2009; Yousefi et al., 2012). Due to high sensitivity of mass spectrometry, 
contents from the few cells that die during cell culture are identified. Alternatively, 
some intracellular proteins may be secreted via exosomes and are identified in 
conditioned media (Gross and Boutros, 2013; Raposo and Stoorvogel, 2013; 
Shimoda and Khokha, 2013; Aoi and Sakuma, 2014). We focused on the 33 
secreted proteins, and identified extracellular 14-3-3 proteins as a promising 
cachexia-inducing candidate because their promiscuous binding and protein 
regulatory activities. 
 
2.4.2 Extracellular 14-3-3 proteins 
14-3-3 proteins are multi-functional and highly conserved binding proteins 
(Freeman and Morrison, 2011; Gardino and Yaffe, 2011; Kleppe et al., 2011; 
Obsil, 2011). They include seven isoforms, which are routinely found in the 
intracellular environment affecting diverse signaling pathways such as 
metabolism, growth, and apoptosis (Freeman and Morrison, 2011; Gardino and 
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Yaffe, 2011; Kleppe et al., 2011; Obsil, 2011). However, several recent studies 
have shown that some isoforms act in an extracellular manner to activate 
signaling cascades. Maksymowych et al. reported that extracellular 14-3-3η was 
elevated in patients with rheumatoid arthritis (RA). THP-1 cells treated with 14-3-
3η showed increased phosphorylation of ERK1/2 and JNK/SAPK and increased 
production of inflammatory transcripts, IL-1β, IL-6, and MMP-1 (Maksymowych et 
al., 2014). In another study, Ghaffari et al. found that extracellular 14-3-3σ 
increased MMP-1 content in fibroblasts (Ghaffari et al., 2010). Similarly, Asdaghi 
et al. found that extracellular 14-3-3α/β induced MMP-1 transcript in lung 
fibroblasts (Asdaghi et al., 2012). Notably, they also found that media conditioned 
with lung cancer cell line, A549, and its control, bronchial epithelial cell line 
HS24, both contained 14-3-3α/β; however, the results for each cell line were 
presented separately, making it impossible to compare extracellular 14-3-3 
content. 
In our study, we compared 14-3-3 content between LCM and C2C12 
myotube conditioned media. When we confirmed the presence of 14-3-3 proteins 
in LCM via western blot, we found that LCM contained lower pan14-3-3 content 
than C2C12-CM (Figure 2.4A). In order to determine whether depletion of 
extracellular 14-3-3 content might contribute to cachexia, we treated myotube 
culture media with an anti-pan14-3-3 antibody. Neutralization of extracellular 14-
3-3 proteins decreased myosin content in myotubes (Figure 2.4B). These data 
suggest that extracellular 14-3-3 proteins are necessary for maintaining myosin 
 
 
	  
 
	  
28 
content in skeletal muscle, however a receptor for extracellular 14-3-3 proteins in 
skeletal muscle was unknown. 
 
2.4.3 CD13: proposed receptor for 14-3-3 proteins 
Previous work by Ghaffari et al. in fibroblasts showed that CD13 may act as 
the receptor for some isoforms of 14-3-3. In their 2010 study, the authors used 
immunofluoresence microscopy and found that 14-3-3σ co-localized with CD13 
(Ghaffari et al., 2010). CD13 is found on many types of stem cells, including 
skeletal muscle satellite cells (Rahman et al., 2014a; Rahman et al., 2014b). 
Using an animal model of ischemic hind-limb injury, Rahman et al. found that 
CD13KO had impaired muscle regeneration compared to WT control mice 
(Rahman et al., 2014a). These findings showed that CD13 is present on muscle 
satellite cells and that it affects skeletal muscle, but its presence on differentiated 
skeletal muscle was unknown. Using immunofluorescence microscopy, we 
confirmed the presence of CD13 on differentiated myotubes, which is in itself a 
novel finding (Figure 2.5A). Our results also showed that LCM treatment 
increased CD13 content in myotubes (Figure 2.5B). Van Hensbergen et al. found 
elevated soluble CD13 (sCD13) in the plasma of cancer patients, and suggested 
that tumors shed CD13 from the plasma membrane (van Hensbergen et al., 
2002). When we examined LCM versus C2C12-CM for sCD13, we found that 
LCM contained elevated sCD13 content (Figure 2.5C). These novel data confirm 
the presence of CD13 on differentiated skeletal muscle and in conditioned media 
from both lung tumors and skeletal muscle. We speculate that sCD13 may bind 
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14-3-3 proteins in the same manner that soluble TNFα receptors capture TNFα: 
soluble CD13 may be the mechanism for extracellular 14-3-3 depletion.  
With the presence of CD13 confirmed in differentiated myotubes, we treated 
myotubes with Bestatin, a potent aminopeptidase inhibitor, to determine if CD13 
is the receptor for 14-3-3 proteins in skeletal muscle. In theory, CD13 inhibition 
should affect skeletal muscle in the same manner as depletion of 14-3-3 proteins. 
In fact, 25µM Bestatin did decrease myosin content, which to our knowledge is a 
novel finding (Figure 2.6A). These results show that aminopeptidases are 
involved in skeletal muscle maintenance, but as Bestatin has multiple targets, we 
needed to inhibit CD13 specifically. However, CD13 neutralization using an anti-
CD13 antibody did not affect myosin content (Figure 2.6B). Interestingly, Ghaffari 
et al. had the opposite result: when they used Bestatin to inhibit the effects of 
extracellular 14-3-3σ via CD13, it had no effect in fibroblasts (Ghaffari et al., 
2010). Their results may indicate that CD13 is not the receptor for 14-3-3σ 
despite co-localization, or, as the authors suggested, that the site of CD13 
enzymatic action may be at an alternate site from that which Bestatin targets. 
There are several epitopes on CD13 targeted by different monoclonal antibodies 
(Xu et al., 1997; Mina-Osorio, 2008; Piedfer et al., 2011). It is possible that the 
antibody we used labeled CD13 without affecting the site where 14-3-3 proteins 
bind. 
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2.4.4 Conclusions 
Extracellular 14-3-3 proteins appear to have a role in maintaining skeletal 
muscle mass, and some isoforms may act as previously unidentified myokines. 
CD13 is a candidate receptor for 14-3-3 proteins, and its soluble form may be the 
mechanism by which 14-3-3 is depleted in LCM. Future studies should include 
determining which individual isoforms of 14-3-3 act in the extracellular space to 
affect skeletal muscle mass, and what role soluble CD13 plays in differentiated 
skeletal muscle. We have proposed a role for extracellular 14-3-3 proteins in 
skeletal muscle and encourage future studies that will delineate the details of this 
previous unidentified pathway.  
This study focused on 14-3-3 proteins and their effect on myosin content. 
However, cancer cachexia is a multifactorial syndrome affecting not only muscle 
mass, but also muscle fatigue. Over the last decade, mitochondrial dysfunction 
had been suggested as a source of fatigue, and future studies are needed to 
determine the source and nature of mitochondrial alternations in cachexia (Filler 
et al., 2014; Lee et al., 2014; Morris et al., 2015).  
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CHAPTER 3 
 
Mitochondria dysfunction in lung cancer-induced muscle wasting in C2C12 
myotubes 
3.1 Introduction 
Malignant tumors alter their surrounding environment via tumor-derived and 
host-derived paracrine factors, which promote cachexia and may also lead to 
mitochondrial dysfunction. Some recent studies found evidence of mitochondrial 
dysfunction in cachexia, which may contribute to muscle pathology (Tan and 
Fearon, 2008; Constantinou et al., 2011; Fearon et al., 2011; Julienne et al., 
2012; Wang et al., 2012; White et al., 2012; Dumas et al., 2013; Fontes-Oliveira 
et al., 2013; Tzika et al., 2013; Julienne et al., 2014). Mitochondria are multi-
functional organelles that provide a majority of ATP to cells, are the major source 
of reactive oxygen species (ROS), and participate in multiple signaling cascades, 
including apoptosis. Reactive oxygen species play an important role in 
maintenance and adaptation of skeletal muscle (Irrcher et al., 2009; Merry et al., 
2010; Dutka et al., 2012; Luo et al., 2013; Michaelson et al., 2013; Prosser et al., 
2013). At low concentrations, ROS function in homeostatic signaling cascades, 
while at high concentrations they cause damage by oxidizing DNA, proteins, and 
lipids (Lee et al., 2012). In skeletal muscle, excessive oxidant production affects 
skeletal muscle mass and function in ways consistent with cachexia (Andrade et 
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al., 1998; Andrade et al., 2001; Reid et al., 2005; Hardin et al., 2008; Gilliam et 
al., 2011).  
In this study, we examined the effect of Lewis lung carcinoma condition 
media (LCM) on mitochondrial function, protein content, and ROS production in 
C2C12 skeletal muscle myotubes. C2C12s are an immortalized cell line of 
mouse skeletal muscle that fuse and differentiate into myotubes under low-serum 
conditions (Yaffe and Saxel, 1977). They are a useful model for studying 
signaling pathways in skeletal muscle under controlled conditions. We chose 
Lewis lung carcinoma as our cancer model because it is known to induce 
cachexia and because lung cancer accounts for 23% of all cancer deaths 
worldwide (Carbo et al., 2004; Argiles et al., 2008; Jemal et al., 2011; Puppa et 
al., 2014). We exposed C2C12 myotubes to LCM for 30min, 2hrs, 4hrs, 24hrs, or 
48hrs, hypothesizing that LCM would impair mitochondrial respiration, increase 
ROS production, and lead to oxidative stress. To test our hypothesis, we 
assessed the following in myotubes: mitochondrial oxygen consumption, content 
of mitochondrial complexes, voltage-dependent anion channel (VDAC), 4-
hydroxynonenal (4HNE), and uncoupling protein 3 (UCP3), the activity of 
cytochrome c oxidase, and oxidant production via DCF, DAF, and Mitosox 
fluorescence.  
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3.2 Materials and methods 
3.2.1 Myotubes 
C2C12 myoblasts (American Type Culture Collection) were plated at a density of 
10,000 cells/cm2 in growth medium {Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% fetal bovine serum, 1.6 g/L sodium bicarbonate, and 100U/ml 
PenStrep (Invitrogen)} and cultured at 37°C in 5% CO2.  Cells reached ~90% 
confluence after 3 days, at which time cells were serum restricted in 
differentiation media (DMEM as above with 2% horse serum replacing fetal 
bovine serum). After 4 days of serum restriction, multinucleated myotubes were 
ready for treatment. Fresh medium was added every 2 days (Moylan et al., 
2014). 
 
3.2.2 Lung cancer cells 
Lewis lung carcinoma cancer cells (LL/2: American Type Culture Collection) were 
seeded at a density of 6000/cm2 in 100mm cell culture plates in growth medium, 
as above. After two days, additional growth media was added to each plate. LL/2 
cells are a heterogeneous mix of floating and adherent cells. After four days, we 
removed growth medium and harvested floating cells by centrifugation at 500xg, 
5 min. Pelleted cells and 10mL differentiation media were added back to the 
adherent cells. After two days, we collected conditioned medium, removed cells 
and debris by centrifugation (500xg, 5 min), and froze aliquots in liquid nitrogen 
for later use. For treatments, we used a 1 in 4 dilution of conditioned media 
mixed with fresh differentiation media.  
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3.2.3 Western blot 
C2C12 myotubes were homogenized in 2X protein loading buffer (120 mM Tris 
pH 7.5, 4% SDS, 200 mM DTT, 20% glycerol, 0.002% bromphenol blue). We 
separated proteins in equal volumes of lysates by SDS-PAGE (4-15% Criterion, 
BioRad) and determined relative total protein by scanning (Odyssey Infrared 
Imaging, LI-COR) stained gels (Simply Blue, Invitrogen). Fluorescence intensity 
data were used to normalize total protein for equal loading. Equal amounts of 
protein were separated by SDS-PAGE and transferred to PVDF membranes for 
western blot using the Odyssey System (Moylan et al., 2014). For preparation of 
mitochondrial and cytosolic fractions, mitochondria were isolated as in Lemire et 
al., and western blots were performed as above (Lemire et al., 2008). 
 
3.2.4 Antibodies 
Primary antibodies were rabbit anti-VDAC and rabbit anti-4 HNE (Abcam), 
mouse anti-Complex I NDUFA9, mouse anti-Complex III, subunit core I, mouse 
anti-Complex IV, subunit IV (Novex), and mouse anti-ATP synthase α 
(Mitosciences).  Secondary antibodies included anti-mouse IRDye 800CW and 
anti-rabbit IRDye 800CW (LI-COR). 
  
3.2.5 Oxidant assays and antioxidant treatments 
To measure cytosolic oxidant activity, we aspirated off the cell culture media, 
replaced it with pre-warmed PBS supplemented with glucose (D-PBS) and 2′,7′-
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dichlorofluorescein diacetate (DCFH-DA 10µM, Molecular Probes). We incubated 
C2C12 myotubes in DCFH-DA for 30 min, 37°C, 5% CO2. After incubation, we 
washed the cells twice with D-PBS, and added fresh D-PBS. To measure nitric 
oxide, we followed the same procedure as above using DAF-FM diacetate (4-
amino-5-methylamino-2',7'-difluorofluorescein diacetate) (DAF-FM 5µM, 
Molecular Probes). We used a spectrofluorometer (Synergy H1, BioTek) to 
measure fluorescence of the oxidized derivatives, DCF (excitation: 480 nm, 
emission 520 nm) and DAF-FM (excitation: 495 nm, emission 515 nm), 
respectively. Antioxidant treatments included either 100µM SS31, a 
mitochondrial-targeted antioxidant, or 5mmol N-Acetylcysteine, a general 
antioxidant (Cho et al., 2007; Whiteman et al., 2008; Manczak et al., 2010; 
Powers et al., 2011). Both were administered simultaneously with LCM 
treatment. 
 
3.2.6 Fluorescence microscopy  
We incubated C2C12 myotubes with MitoSox (5µM, Molecular Probes), a 
mitochondrial superoxide anion specific indicator, for 30 minutes. Cells were 
rinsed twice with pre-warmed 1X PBS supplemented with glucose and sodium 
pyruvate. We captured live cell fluorescence images (excitation: 510 nm, 
emission 580 nm) using a CCD camera (CoolSNAP-ES, Roper Scientific 
Photometrics) attached to a Nikon TE2000 microscope with NIS Elements image 
acquisition software (Nikon). 
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3.2.7 Oxygen consumption rate 
We cultured C2C12 myotubes as above in XFe24 Analyzer plates (Seahorse 
Bioscience). Before running the assay, we replaced differentiation media with 
Seahorse assay medium supplemented with 10mM sodium pyruvate and 10mM 
glucose, and we adjusted the pH to 7.4. Seahorse assay medium is non-buffered 
for measuring proton production. Plates were equilibrated in this medium for one 
hour at 37°C with no CO2. We used the same media as vehicle for our injection 
compounds. The analyzer sequentially injected the following compounds: 
oligomycin (1µM final concentration), which blocks ATP synthase and shows the 
OCR dedicated to ATP production; carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone (FCCP: 4µM final concentration), which permeabilizes the inner 
mitochondrial membrane and shows maximal OCR; and rotenone (1µM final 
concentration), which blocks complex I and shows NADH-driven OCR. There 
were 3-4 wells per treatment group, and 4 plates in total. We measured OCR at 
three time points during basal respiration and after each injection using a 
Seahorse XFe24 Flux Analyzer (Seahorse Biosciences). We normalized OCR 
measurements to VDAC content in each well determined via western blot. 
  
3.2.8 Cytochrome c oxidase activity 
We measured mitochondrial complex IV activity using a Cytochrome Oxidase 
assay kit (Biovision) per manufacturer’s protocol. Briefly, we lysed C2C12 
myotubes by 3 freeze-thaw cycles in 20mM hypotonic potassium phosphate 
buffer pH 7.5 supplemented with protease and phosphatase inhibitor cocktails 
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(Sigma). In a 96 well plate, we added Cytochrome c and Cytochrome Oxidase 
Assay Buffer (Biovision) to 2 µg total protein and recorded the decrease in optical 
density (OD) at 550nm over 45 minutes using a spectrophotometer (Synergy H1, 
BioTek). The decrease in optical density is proportional to an increase in oxidized 
cytochrome c. We derived activity from the reaction rate in the linear phase, i.e. 
cytochrome oxidase activity (Units/mg) =  {(OD1-OD2)/(t1-t2)}/(ε x mg protein), 
where ε is the molar extinction coefficient of cytochrome c at 550nm (7.04 mM-
1cm-1) and one unit oxidizes one µmole reduced cytochrome c per minute. 
 
3.2.9 Statistics 
Prism 5.0b (GraphPad Software) and SAS served as our statistics software. We 
used t-test, one-way ANOVA and post hoc Bonferroni test, or repeated measures 
ANOVA as appropriate. Data are presented as mean +/- SE. Statistical 
significance was defined as p<0.05.  
 
3.3 Results 
3.3.1 Pre-treatment with LCM decreases mitochondrial respiration  
To assess how LCM affects mitochondrial function in skeletal muscle, we 
examined C2C12 myotubes after 30 minutes, 2hrs, or 24hrs in LCM. LCM 
treatment altered respiration in a time-dependent manner (Figure 3.1A). Western 
blot showed that VDAC content is unaffected by LCM treatment; therefore, we 
normalized OCR to VDAC content (Figure 3.1B). Thirty minutes of LCM 
treatment did not affect electron transport chain (ETC) activity; however, 2hrs or 
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24hrs of LCM treatment resulted in depressed basal respiration (Figure 3.1C). 
The difference between basal respiration and oligomycin-sensitive respiration 
represents the OCR dedicated to ATP production. Compared to control 
myotubes, myotubes exposed to 2hrs or 24hrs of LCM had significantly less 
ATP-related OCR (Figure 3.1D).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Oxygen consumption rate (OCR) in C2C12 myotubes. Eleven total 
OCR measurements were taken over 2hrs by injecting an inhibitor or uncoupler 
(1=oligomycin, 2=FCCP, 3=Rotenone): 3 basal respiration, (1) 3 Oligomycin-
sensitive respiration, (2) 3 maximal respiratory capacity, and (3) 2 non-
mitochondrial respiration. The x-axis is time. (A) OCR normalized to VDAC 
 
Time 
  1         2      3  
	  
 
	  
39 
content presented at % basal control in control myotubes versus myotubes 
treated for 30 min, 2hrs or 24hrs with LCM (n=12, *P<.01 for treatment effect, 
repeated measures ANOVA). (B) VDAC content in myotubes treated with LCM, 
represented as percent control. (C) Change basal respiration in myotubes treated 
with LCM, expressed as percent of control respiration (n=12, *P <0.01, ANOVA, 
Bonferroni post hoc). (D) ATP-related OCR/VDAC in myotubes treated with LCM 
expressed as percent basal control (n=12, *P <0.05, ANOVA, Bonferroni post 
hoc test).  
 
3.3.2 Protein content of mitochondrial complexes in C2C12 myotubes treated 
with LCM  
To test whether the decreased mitochondrial respiration in LCM-treated 
myotubes was caused by changes in ETC complexes, we measured their 
content by western blot. Each complex in the ETC has multiple subunits, and we 
measured a representative subunit for each complex as follows: mitochondrial 
complex I NDUFA9; complex III subunit core I; complex IV subunit IV; and 
complex V, subunit α. LCM treatment did not alter the content of any ETC 
complex subunit measured (Figure 3.2).  
 
 
Figure 3.2 Protein content of electron transport chain complexes. Samples 
were equal protein loaded, which was determined via SDS-PAGE and staining 
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with Simply Blue. Western blot membranes showed no changes in protein 
content for mitochondrial complex I NDUFA9, complex III subunit core I, complex 
IV subunit IV, and complex V, subunit α (n=6). 
 
 
3.3.3 Effect of LCM treatment on cytochrome c oxidase activity 
Cytochrome c oxidase is the last complex in the electron transport chain.  It 
transfers four electrons to molecular oxygen. A decrease in cytochrome c 
absorbance indicates an increase in cytochrome c oxidase activity. Cytochrome c 
oxidase activity in myotubes treated with LCM for 2hrs increased compared to 
control myotubes (Figure 3.3). These results suggest that there is an early burst 
of cytochrome c oxidase activity upon exposure to LCM.  
 
                
Figure 3.3 The effect of LCM treatment on cytochrome c oxidase activity. 
(A) Cytochrome C absorbance decreases after a 2hr exposure to LCM, 
indicating an increase in cytochrome c oxidase activity. (B) Cytochrome oxidase 
activity defined by the rate of change in the linear range per mg protein. LCM 
treatment for 2hrs increased activity to 144% of control (n=8. *P<0.01, t-test).  
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3.3.4 LCM-induced changes in oxidant production  
The ETC constitutively produces reactive oxygen species (ROS) during activity 
and is the greatest source of oxidants in skeletal muscle (Turrens, 2003). It is 
therefore likely that changes in ETC activity are reflected in alterations in ROS 
production. To test our hypothesis that LCM treatment would alter the level of 
oxidants, we examined general oxidant production, reactive nitrogen species 
(RNS) production, and mitochondrial superoxide anion production in myotubes 
treated with LCM for 30 minutes, 4hrs, 6hrs, and 24hrs. DCF fluorescence 
measures overall cytosolic oxidant activity. Cytosolic oxidants increased at 30 
minutes and 4hrs compared to control myotubes (Figure 3.4A). However, after 
24hrs of LCM treatment, cytosolic oxidants decreased (Figure 3.4A). DAF 
fluorescence, which measures RNS production, was unaltered by LCM 
treatments (Figure 3.4B). These data indicated that RNS did not contribute to 
changes in overall cytosolic oxidant activity, as measured by DCF fluorescence. 
We hypothesized that some of the changes in DCF fluorescence might originate 
from the ETC. Using a CCD camera attached to a fluorescence microscope, we 
tested our hypothesis by measuring changes to the fluorescence intensity of 
mitochondrial superoxide indicator, MitoSox, in myotubes treated with LCM, LCM 
combined with mitochondrial-targeted antioxidant, SS31, and LCM combined 
with general antioxidant, N-Acetylcysteine (NAC). We found that after 2hrs of 
LCM treatment, MitoSox fluorescence increased compared to control myotubes 
(Figures 3.4C, 3.4D). Myotubes treated for 2hrs with LCM combined with 
mitochondrial antioxidant, SS31, had reduced MitoSox fluorescence compared to 
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myotubes treated with LCM alone (Figure 3.4D). Myotubes treated with LCM 
combined with NAC had no significant alteration in MitoSox fluorescence (Figure 
3.4D). 
 
 
 
Figure 3.4 LCM treatment alters oxidant production. (A) DCFH 
fluorescence, a measurement of cytosolic oxidant levels, was increased 
by LCM treatment for 30 minutes and 4hrs, but reduced by 24hrs of 
treatment, represented as percent change (n=10, *P<0.05, ANOVA, 
Bonferroni post hoc). (B) Unaltered DAF fluorescence in myotubes treated 
with LCM for 30 minutes, 2hrs, and 24hrs, represented as percent change 
(n=20, non-significant, ANOVA, Bonferroni post hoc). (C) Fluorescence 
images of control myotubes (top panel) and LCM-treated myotubes 
(bottom panel) treated with MitoSox. (D) 2hrs of LCM treatment increased 
MitoSox fluorescence compared to control; 2hrs of LCM treatment 
combined with SS31 decreased Mitosox fluorescent compared to LCM-
treated myotubes; and 2hrs of LCM treatment combined with NAC did not 
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alter MitoSox fluorescence significantly (n=4, *P<0.05, Bonferroni post 
hoc). 
 
3.3.5 Effect of LCM treatment on UCP3 content  
The DCF results with 24hrs of LCM treatment are consistent with ETC 
uncoupling. UCP3 is the most abundant uncoupling protein in skeletal muscle, 
and we speculated that its expression may be elevated with prolonged LCM 
exposure as a protection against LCM-induced oxidative damage by reducing 
ROS production (MacLellan et al., 2005; Toime and Brand, 2010). We examined 
the content of UCP3 via western blot and found that its expression was 
unaffected by LCM treatment (Figure 3.5).  
 
 
Figure 3.5 The effect of LCM treatment on UCP3 content. The left panel 
shows a representative western blot with anti-UCP3 in control and LCM-treated 
myotubes. The right panel shows the quantification of western blot represented 
as percent control (n=6, t-test). 24hrs of LCM treatment does not alter UCP3 
content. 
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3.3.6 Effect of LCM treatment on protein oxidation 
LCM treatment caused a transient increase in ROS, potentially leading to 
oxidized proteins that may affect ETC activity (Figure 3.4). We isolated 
mitochondria from myotubes treated for 2hrs or 48hrs with LCM. After 2hrs of 
LCM treatment, 4-hydroxynonenal (HNE) was elevated in the cytosolic fraction, 
and after 48hrs, HNE was elevated in both cytosolic and mitochondrial fractions 
(Figure 3.6). These data indicate that LCM oxidizes both cytosolic and 
mitochondrial proteins, which may result in alterations to their functions. 
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Figure 3.6 LCM treatment oxidizes proteins. The upper panel shows western 
blot for anti-4HNE in cytosolic and mitochondrial myotube fractions treated with 
LCM for 2hrs or 48hrs, versus control myotubes. The bottom panel shows the 
quantification anti-4HNE western blots (n=4, P<0.05, ANOVA, Bonferroni post 
hoc). LCM treatment for 2hrs and 48hrs increased HNE content in both cytosolic 
and mitochondrial portions of cell lysates. Experiment performed by Jennifer 
Moylan, Ph.D. 
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3.4 Discussion 
Mitochondrial dysfunction has been reported in several models of cancer 
cachexia; however, there have been conflicting data regarding the nature of 
alterations to the ETC (Busquets et al., 2005; Constantinou et al., 2011; Julienne 
et al., 2012; Khamoui and Kim, 2012; Tzika et al., 2013). One primary feature of 
cachexia is that the remaining muscle mass becomes easily fatigued, suggesting 
possible ETC dysfunction. For example, alterations to the ETC could promote 
fatigue through loss of ATP production, increased production of ROS, or both 
(Roberts et al., 2013a; Roberts et al., 2013b). Previous studies have found that 
excessive ROS oxidize myofibrillar proteins in skeletal muscle, and it is 
reasonable to hypothesize that ROS may also contribute to cachectic fatigue in 
this manner (Bruton et al., 2008; Prochniewicz et al., 2008a; Prochniewicz et al., 
2008b; Reid, 2008; Fedorova et al., 2010). In this study, we used an in vitro 
model of cancer cachexia to focus on the direct action of cancer-conditioned 
media on mitochondrial function, protein content, ROS production, and oxidative 
stress in skeletal muscle.  
 
3.4.1 Time-dependent alteration of ETC activity 
Our results show that LCM changed ETC activity in C2C12 myotubes in a 
time-dependent manner (Figure 3.1A). ETC activity was altered by LCM 
treatment. LCM exposure of 2hrs and 24hrs lead to depressed basal respiration 
and ATP-related OCR (Figure 3.1C-D). The altered ETC activity with longer 
treatment times could have several possible explanations: less mitochondria in 
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LCM-treated cells, reduced content of mitochondrial complexes, or increased 
ROS production. We tested protein content of VDAC as a measurement of 
mitochondrial content and found it unaffected by LCM treatment (Figure 3.1B). 
With this finding, we used VDAC as a means of normalization in XF analyzer 
measurements of OCR. We also measured the protein content of ETC 
complexes I, III, IV, and V, and found that LCM treatment did not alter expression 
(Figure 3.2). With content of mitochondria and the complexes remaining intact, 
alterations to complex activity became a candidate to explain our OCR results. 
Complex IV, cytochrome c oxidase, is the last electron carrier of the ETC, 
passing four electrons from reduced cytochrome c to molecular oxygen to 
produce water. If complex IV activity is diminished, it suggests that electron 
transport is slowed. We found that 2hrs of LCM treatment increased Complex IV 
activity, which seems to contradict our hypothesis (Figure 3.3). However, Turrens 
found that ETC-generated superoxide can reduce cytochrome c directly leading 
to increased Complex IV activity while bypassing complexes I and III (Turrens, 
2003). In other words, the activity could increase if more reduced cytochrome c 
substrate was present due to an increase in superoxide production.  
 
3.4.2 LCM-treatment alters ROS  
The complex IV activity data suggested the possibility that LCM treatment 
caused an increase in ROS production. Although normal physiological activity of 
the ETC constitutively produces some ROS as electrons slip off of complexes I 
and III, excessive oxidant production is known to cause oxidation damage to 
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proteins, lipids, and DNA (St-Pierre et al., 2002; Turrens, 2003). We 
hypothesized that LCM treatment was inducing excessive oxidant production, 
leading to oxidative stress in our model. LCM treatment initially increased oxidant 
production, but by 24hrs after treatment, oxidants were depressed below control 
conditions (Figure 3.4A). Lack of changes in DAF fluorescence rejected 
contributions from alterations in RNS in our system (Figure 3.4B). Increased 
MitoSox fluorescence with LCM treatment implicated mitochondrial superoxide 
as a source for the initial rise in oxidant production (Figure 3.4C). This hypothesis 
was supported by additional experiments in which we showed a decrease in 
MitoSox fluorescence when LCM treatment was combined with mitochondrial 
targeting antioxidant, SS31, but not with general antioxidant, NAC (Figure 3.4C-
D) An increase in superoxide may also explain our increase in cytochrome c 
oxidase activity. 
 
3.4.3 LCM-treatment and uncoupling 
Depressed oxidant production after 24hrs of LCM treatment suggested that 
uncoupling may occur in our model. Uncoupling increases in response to 
elevated ROS production as a means of reducing ROS and the potential damage 
they inflict (MacLellan et al., 2005; Toime and Brand, 2010). Mitochondria are 
considered uncoupled when electrons move through the inner mitochondrial 
membrane without participating in ATP production. Other studies on cachectic 
skeletal muscle have found both increased and unchanged expression of 
uncoupling protein three (UCP3), the main uncoupling protein in skeletal muscle 
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(Vidal-Puig et al., 1997; Constantinou et al., 2011; Julienne et al., 2012; Antunes 
et al., 2014). We found no change in the expression of UCP3 despite the 
depression in ROS production (Figure 3.5). With UCP3 unchanged, we 
hypothesized that oxidative damage might affect ETC activity, leading to a 
subsequent decrease in ETC-generated ROS production over time. 
 
3.4.4 LCM-treatment increases oxidative stress 
We tested the effect of LCM treatment on oxidative stress. 4-hydroxynonenal 
is a product of lipid peroxidation, and acts as both a marker and inducer of 
oxidative stress. It is known to aggregate and cause oxidative damage to DNA 
and proteins (Chen and Niki, 2006). We tested for 4HNE-modified proteins in 
cytosolic and mitochondrial fractions of myotube lysates via anti-4HNE western 
blot. We found that LCM increased 4HNE modifications to proteins in both 
fractions after 48hrs (Figure 3.6). These data show that LCM causes oxidative 
damage, perhaps affecting ETC activity.  
 
3.4.5 Conclusions 
 Our results show that skeletal muscle cells treated with LCM experience 
altered ETC activity, including reduced basal respiration and reduced ATP-
related OCR. LCM treatment initially induces a burst of ROS production, some of 
which is mitochondrial superoxide. Our 4HNE results show that LCM induced 
oxidative damage. 4HNE itself can act as a mediator of oxidative stress, and 
potentially creates a self-amplifying loop of oxidative stress. Both ROS and 4HNE 
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can damage DNA, proteins, transcription factors, and lipids, resulting in 
widespread cellular damage. Future work should focus on finding therapeutics 
which alleviate mitochondrial stress in cachexia.  
One promising mechanism for addressing cachexia-related mitochondrial 
dysfunction is by inhibiting cyclooxygenase-2. Clinical trials using COX2 
inhibitors to treat cachexia noted decreased fatigue in some patients (Mantovani 
et al., 2010). While no mechanism was suggested, these results hint that COX-2 
inhibitors may affect mitochondria, which lead us to study this previously 
unexplored relationship. 
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CHAPTER 4 
	  
The Effect of Cyclooxygenase-2 inhibitor, NS-398, on skeletal muscle 
mitochondrial function in lung cancer-induced cachexia 
 
4.1 Introduction 
COX-2 is up-regulated in malignant tumors and in cachectic skeletal 
muscle, and is an established linchpin of tumorigenesis (Hida et al., 1998; 
Balkwill and Mantovani, 2001; Mantovani et al., 2008; Balkwill and Mantovani, 
2010). In fact, people who take COX-2 inhibitors are less likely to develop certain 
types of tumors (Takada et al., 2004; Backhus et al., 2006; Inoue and Aramaki, 
2007; Ali et al., 2010; Peulen et al., 2013; Zhang et al., 2013; Zhang et al., 2014). 
COX-2 is an inflammatory enzyme that converts arachidonic acid to prostanoids. 
Under physiological conditions, prostanoids are multifunctional regulators of 
muscle growth, gastric mucosa, parturition, and the acute inflammatory response 
to injury. In excess, prostanoids are instigators of chronic inflammation, but they 
can be modulated with selective inhibitors of COX-2 (Ricciotti and FitzGerald, 
2011; Trappe and Liu, 2013).  
Clinical trials have shown that COX-2 inhibitors are moderately successful 
at treating cachexia (Baumgarten et al., 2007; Mantovani et al., 2010). There 
appear to be multiple mechanisms by which COX-2 inhibitors restore muscle 
mass. For example, they reduce production of cachectic cytokines, such as TNF-
α and IL-6, which are elevated in the sera of cancer patients (Baumgarten et al., 
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2007; Mantovani et al., 2010). It is interesting to note, however, that clinical trials 
for one-target inhibitors of cachectic cytokines, including TNF-α, have proven 
ineffective (Mantovani et al., 2010). Overall, COX-2 inhibition is an appealing 
strategy because it has beneficial results in skeletal muscle while also working in 
opposition to tumor-growth, a relationship that must be considered for cachexia 
therapeutics. 
Along with muscle restoration, clinical trials for COX2 inhibitors also noted 
decreased fatigue in some patients (Mantovani et al., 2010). No mechanism was 
suggested, but these results hint that COX-2 inhibitors may affect cancer-induced 
mitochondrial dysfunction. Mitochondria are multi-functional organelles that make 
a majority of our ATP, are the major source of reactive oxygen species (ROS), 
and are integral to many signaling cascades. In this study, we assessed the 
effect of simultaneously treating C2C12 myotubes with LCM and a COX-2 
inhibitor, NS-398. We tested myosin content, mitochondrial oxygen consumption 
rate, mitochondrial membrane potential, and production of ROS. To our 
knowledge, this is the first study to examine the relationship between COX2 
inhibition and mitochondrial function in cancer cachexia. 
  
4.2 Materials and methods 
4.2.1 Myotubes 
C2C12 myoblasts (American Type Culture Collection) were plate at 10,000 
cells/cm2 in growth medium {Dulbecco’s modified Eagle’s medium (DMEM) with 
10% fetal bovine serum (FBS), 1.6 g/L NaHCO3, and 100U/ml PenStrep 
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(Invitrogen)} and grown at 37°C in 5% CO2. Cells reached ~90% confluence after 
3 days, and we serum-restricted the cells in differentiation media (DMEM as 
above with 2% horse serum replacing FBS). After 4 days, multinucleated 
myotubes were ready for treatment. Fresh medium was added every 2 days 
(Moylan et al., 2014). Treatments included 50µM NS-398, a selective COX-2 
inhibitor, with or without simultaneous treatment with lung-cancer conditioned 
media (LCM) for 24-48hr. 
 
4.2.2 Cancer cells and conditioned media 
Lewis lung carcinoma cells (LL/2: American Type Culture Collection) were 
seeded at a density of 6000 cells/cm2 in 100mm cell culture plates with growth 
medium (as above). After two days, supplementary growth media was added to 
each plate. LL/2 cells contain adherent and floating cells. After four days, we 
removed growth medium, and harvested floating cells by centrifugation at 500xg, 
5 min. Pelleted cells and differentiation media were added back to the plate 
containing the adherent cells. After two days, we collected conditioned media 
(LCM) and cleared it of cells and debris by centrifugation (500xg, 5 min). Aliquots 
were frozen in liquid nitrogen for later use. For treatments, conditioned media 
were diluted 1 in 4 with fresh differentiation media (McLean et al., 2014). Cancer 
cell treatments included 1-20µM NS-398 for 48hr. 
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4.2.3 Western blot 
We homogenized C2C12 myotubes in 2X protein loading buffer (120 mM Tris pH 
7.5, 4% SDS, 200 mM DTT, 20% glycerol, 0.002% bromphenol blue). Proteins 
were separated in equal volumes of lysates by SDS-PAGE (4-15% Criterion, 
BioRad). Relative total protein was determined by scanning (Odyssey Infrared 
Imaging, LI-COR) the stained gels (Simply Blue, Invitrogen). We used 
fluorescence intensity data to normalize total protein for equal loading. SDS-
PAGE was used to separate equal amounts of protein, which was then 
transferred to PVDF membranes for western blot using the Odyssey System 
(Moylan et al., 2014). 
 
4.2.4 In-cell western  
Myosin content was measured in intact myotubes using the Odyssey In-Cell 
western system (LI-COR). Briefly, myotubes were fixed with 4% formaldehyde 
and permeabilized with 0.1% Triton-X 100 (Sigma). Myotubes were blocked in a 
1:1 mixture of 1X PBS and Odyssey blocking buffer (LI-COR). Primary antibody 
for myosin was diluted 1:500, and secondary antibody to 1:800. The plate was 
scanned on the Odyssey System. Myosin was normalized to total protein by 
staining with Simply Blue (Invitrogen) and measuring fluorescence intensity. 
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4.2.5 Antibodies 
For western blot, we used rabbit anti-cyclooxygenase-2 (Cell Signaling) and 
mouse anti-myosin (Sigma) as primary antibodies, and anti-mouse IRDye 
800CW (LI-COR) as the secondary.  
 
4.2.6 Oxidant assays  
To measure cytosolic oxidant activity, we aspirated off the cell culture media, 
replaced it with pre-warmed PBS supplemented with glucose (D-PBS) and 2′,7′-
dichlorofluorescin diacetate (DCFH-DA 10µM, Molecular Probes). C2C12 
myotubes were incubated in DCFH-DA for 30 min, 37°C, 5% CO2. After 
incubation, we washed the cells twice with D-PBS, added fresh D-PBS, and used 
a spectrofluorometer (Synergy H1, BioTek) to measure fluorescence of the 
oxidized derivative, DCF (excitation: 480 nm, emission 520 nm).  
 
4.2.7 Fluorescence microscopy  
For measuring mitochondrial membrane potential, we aspirated off the cell 
culture media, replaced it with pre-warmed PBS supplemented with glucose (D-
PBS) and Mitotracker CMXros (250nM, Molecular Probes), a live cell, 
potentiometric mitochondrial dye.  After incubation, we washed the cells twice 
with D-PBS, added fresh D-PBS, and captured live cell fluorescence images 
(excitation: 579 nm, emission 599 nm) using a CCD camera (CoolSNAP-ES, 
Roper Scientific Photometrics) attached to a Nikon TE2000 microscope with NIS 
Elements image acquisition software (Nikon). Fluorescence images were 
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processed with ImageJ (NIH). To measure mitochondrial oxidant production, we 
incubated C2C12 myotubes with MitoSox (5µM, Molecular Probes), a 
mitochondrial superoxide anion specific indicator, for 15 minutes, as above. We 
captured live cell fluorescence images (excitation: 510 nm, emission 580 nm) 
and processed the images as above. 
 
4.2.8 Oxygen consumption rate 
We cultured C2C12 myotubes as above in XFe24 Analyzer plates (Seahorse 
Bioscience). Before running the assay, differentiation media was replaced with 
Seahorse assay medium supplemented with 10mM sodium pyruvate and 10mM 
glucose, pH adjusted to 7.4. Seahorse assay medium is non-buffered for 
measuring proton production. Plates were equilibrated in this medium for one 
hour at 37°C with no CO2. We used the same media as vehicle for our injection 
compounds. The analyzer sequentially injected the following compounds: 
oligomycin (1µM final concentration), which blocks ATP synthase and shows the 
OCR dedicated to ATP production; carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone (FCCP: 4µM final concentration), which permeabilizes the inner 
mitochondrial membrane and shows maximal OCR; and rotenone (1µM final 
concentration), which blocks complex I and shows NADH-driven OCR. There 
were 3-4 wells per treatment group, and 4 plates in total. We measured OCR at 
three time points during basal respiration and two or three times after each 
injection using a Seahorse XFe24 Flux Analyzer (Seahorse Biosciences). We 
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normalized OCR measurements to VDAC content in each well determined via 
western blot (McLean et al., 2014) 
 
4.2.9 Statistics 
Prism 5.0b served as our statistics software (GraphPad Software).  We 
used ANOVA, or repeated measures ANOVA, with Dunnett’s or Bonferroni post-
test for multiple comparisons, and t-test for all other comparisons. Data are 
presented as mean +/- SE. Statistical significance was defined as p<0.05. 
 
4.3 Results 
4.3.1 LCM-treatment increases cyclooxygenase-2 content in myotubes 
Cancer is a chronic inflammatory disease that increases production of 
inflammatory factors, including cyclooxygenase-2 (COX-2). In order to verify the 
inflammatory state of our cancer cachexia model, we treated C2C12 myotubes 
with LCM for 48hr and used western blot to measure COX-2 content. LCM 
treatment increased COX-2 content (Figure 4.1). 
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Figure 4.1 LCM-treatment increases cyclooxygenase-2 content. COX-2 
content increases in myotubes treated with LCM for 48hr (n=6, t-test, *P<0.05). 
 
4.3.2 Cyclooxygenase-2 inhibition does not alter myosin content in myotubes 
Both clinical trials and in vivo animal models have shown some success in 
using COX-2 inhibitors to restore muscle mass in cachexia (Baumgarten et al., 
2007; Xu et al., 2015). It was unknown whether the muscle sparing was a result 
of direct interaction with skeletal muscle, or an indirect effect via some other cell 
type. We treated myotubes with LCM or LCM combined with of COX-2 inhibitor, 
50µM NS-398, and measured myosin content with western blot. COX-2 inhibition 
did not spare myosin content (Figure 4.2A). We had similar results at 
concentrations ranging from 10nM to 100µM (data not shown). COX-2 inhibition 
in vivo may work by affecting the tumor itself, which indirectly leads to restoration 
of skeletal muscle. We treated Lewis lung carcinoma cells (LL/2) with 1-20µM 
NS-398, and then treated myotubes with conditioned media from the NS-398 
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treated LL/2 cells. Treating the tumor cells with NS-398 did not prevent myosin 
loss (Figure 4.2B). 
 
 
Figure 4.2 COX-2 inhibition does not alter myosin content. A) Western blot 
for myosin showed that treating myotubes for 24hr with LCM reduced myosin 
content and that LCM combined with 50µM NS-398 did not spare myosin 
content (n=4, ANOVA with Bonferroni post test, *P<0.05). B) In-cell western blot 
for myosin showed that treating LL/2 tumors cells with NS-398 for 48hr did not 
alter how conditioned media affected myotubes (n=4, ANOVA with Dunnett post 
test, *P<0.05).  
 
4.3.3 COX-2 inhibition alters mitochondrial respiration in LCM-treated myotubes 
We have previously shown that LCM treatment reduces mitochondrial 
oxygen OCR in C2C12 myotubes (McLean et al., 2014). The effect of COX-2 
inhibition on mitochondrial respiration in LCM-treated myotubes was unknown. 
We treated C2C12 myotubes with 50µM NS-398, LCM, or LCM combined NS-
398 for 24hr. LCM-treatment significantly reduced all respiration conditions 
(Figure 4.3A-D).  For basal, oligomycin-sensitive, and rotenone-sensitive 
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respiration, LCM/NS-398 increased OCR compared to LCM treatment alone 
(Figure 4.3A-B,D).   
 
 
 
Figure 4.3 Mitochondrial respiration in control and LCM-treated myotubes 
after COX-2 inhibition. For clarity, graphs shown are the averages of 3 
measurements for basal, oligomycin-sensitive, and maximal respiration, and two 
measurements for rotenone-sensitive respiration. An asterisk indicates that all 
measurements for a given respiration condition were significant (n=4, repeated 
measures ANOVA with Bonferroni post test, *p<0.05). A) Basal respiration in 
LCM-treated myotubes was lower compared to control and to LCM/NS-398. B) 
ATP-related respiration in LCM-treated myotubes was lower compared to 
control and to LCM/NS-398. C) Maximal respiration in LCM-treated myotubes 
was lower compared to control. D) Rotenone-sensitive respiration in LCM-
treated myotubes was lower compared to control and to LCM/NS-398. 
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4.3.4 COX-2 inhibition does not affect mitochondrial membrane potential in LCM-
treated myotubes 
Loss of mitochondrial membrane potential (MMP) triggers signaling cascades 
associated with programmed cell death. Therefore, MMP is an important 
indicator of cell health.  In order to determine if LCM compromises MMP, we 
treated myotubes for 24hr with LCM, NS-398, or LCM/NS-398. We tested MMP 
using a potentiometric dye, mitotracker CMXros. None of the treatments altered 
MMP (Figure 4.4).  
 
 
Figure 4.4 COX-2 inhibition by NS-398 does not alter MMP. Treatment 
with LCM, NS-398, and LCM+NS-398 did not alter mitochondrial membrane 
potential (n=4, ANOVA with Bonferroni post test, n.s.). 
 
 
4.3.5 COX-2 inhibition restores cytosolic oxidants in LCM-treated myotubes to 
control levels  
We have previously shown that production of reactive oxygen species (ROS) 
is initially elevated when myotubes are treated with LCM, but by 24hr after 
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treatment, cytosolic oxidants are reduced compared to control levels, reflecting a 
reduction in electron transport chain activity (McLean et al., 2014). The alteration 
of mitochondrial respiration in LCM/NS-398 treated myotubes in Figure 4.3 
should be mirrored in oxidant production, supporting the hypothesis that COX-2 
inhibition affects mitochondrial function. Using DCFH fluorescence, we tested 
cytosolic oxidant levels after 24hr of treatments. LCM decreased cytosolic 
oxidants levels, while LCM/ NS-398 was similar to control levels (Figure 4.5A). 
We also tested mitochondrial oxidant production after 24hr using MitoSox 
fluorescence and found that no treatment altered mitochondrial oxidants 
compared to control (Figure 4.5B). 
 
 
 
Figure 4.5 COX2 inhibition alters cytosolic, but not mitochondrial, oxidant 
levels in LCM-treated myotubes. Compared to control myotubes, DCFH 
fluorescence was reduced in LCM-treated myotubes, and, compared to LCM-
treated myotubes, DCFH was higher in LCM/NS-398 treated myotubes. (n=6, 
ANOVA with Bonferroni post test, *P<0.05). B) After 24hr treatment, MitoSox 
fluorescence was unaltered by LCM or LCM/NS398 treatment (n=4, ANOVA 
with Bonferroni post test, n.s.). 
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4.4 Discussion  
 
In clinical trials, COX-2 inhibitors restore skeletal muscle in cachectic 
patients (Baumgarten et al., 2007; Mantovani et al., 2010; Xu et al., 2015). Lai et 
al. found that cachectic patients taking celecoxib had a significant increase in 
quality of life and a non-significant increase in body weight compared to those 
taking the placebo; these results occurred in three weeks (Lai et al., 2008). In 
another study in which advanced cancer patients took celecoxib for sixteen 
weeks, subjects significantly gained lean body mass and increased grip strength 
(Mantovani et al., 2010). Although muscle sparing in these clinical trials was 
incomplete, COX-2 inhibitors are some of the most successful single-target 
drugs tested for cachexia. COX-2 inhibitors are also appealing because they are 
generally well tolerated, already have FDA approval, are cost effective, and are 
anti-tumorigenic. The mechanism of muscle restoration by COX-2 inhibition may 
be multi-factorial, and their effect on skeletal muscle mitochondrial function was 
unknown. Mitochondria provide most of the body’s ATP and participate in 
important signaling cascades, including programmed cell death; their function is 
vital to health. The goal of the current study was to assess how COX-2 inhibition 
affects mitochondrial function during cancer cachexia. 
 
4.4.1 LCM increases inflammation in myotubes 
Cancer is widely known as a disease of inflammation (Balkwill and 
Mantovani, 2001; Balkwill and Mantovani, 2012; Tsoli and Robertson, 2013). 
Inflammatory factors, such as TNFα, IL-6, and COX-2 are elevated in tumors and 
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in sera from cancer patients (Balkwill and Mantovani, 2010; Balkwill and 
Mantovani, 2012; Tsoli and Robertson, 2013). An increase in inflammatory 
factors, including COX-2, has been seen in cachectic skeletal muscle as well 
(Baumgarten et al., 2007). LCM treatment increased COX-2 content to 175% of 
control and confirmed the inflammatory state of our model (Figure 4.1). Our initial 
experiments tested the most direct mechanism by which COX-2 inhibitors may 
restore skeletal muscle during cachexia: we examined whether the inhibitors 
acted directly on the skeletal muscle itself.  
 
4.4.2 COX-2 inhibition does not spare myosin content 
Although these were straightforward experiments, we found that information 
in the literature was scarce. This may be because COX-2 inhibition in non-
cachectic skeletal muscle actually impedes healing, and therefore would seem 
an unlikely agent of skeletal muscle restoration (Bondesen et al., 2004; 
Weinheimer et al., 2007; Shen et al., 2008; Markworth and Cameron-Smith, 
2013; Trappe and Liu, 2013). Or, this paucity may also reflect negative data 
similar to our results. Indeed, when we tested myosin content in myotubes 
treated with LCM/NS-398, we found that myosin, which is preferentially degraded 
in cachexia, was not spared (Figure 4.2A); (Banduseela et al., 2007; Schmitt et 
al., 2007; Attaix et al., 2008; Ochala and Larsson, 2008)). Some reviews have 
suggested that in vivo, COX-2 inhibitors reduce tumor burden and thus indirectly 
affect muscle mass as a result. When we treated LL/2 tumors cells with NS-398 
and then used the altered LCM to treat myotubes, myosin content was still 
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reduced (Figure 2B). These results suggest that the mechanism by which COX-2 
inhibitors restore muscle mass in vivo may occur indirectly through other tissue 
or cell types. Despite the lack of direct effect on myosin, we wondered if COX-2 
inhibition affects mitochondrial function, which could account for the 
improvements in fatigue seen in clinical trials. 
 
4.4.3 COX-2 inhibition alters mitochondrial OCR 
Previous studies from our lab and others have shown that mitochondrial 
function is impaired in cachectic skeletal muscle (Julienne et al., 2012; Tzika et 
al., 2013; Antunes et al., 2014; McLean et al., 2014). However, to our knowledge, 
no study examined cachectic mitochondrial dysfunction in relation to COX-2 
inhibition. We found that inhibiting COX-2 increased oxygen consumption in 
LCM-treated myotubes under all respiration conditions we tested (Figure 4.3A-
D). Our results suggested that it is possible to treat cachectic mitochondrial 
dysfunction by inhibiting COX-2, although the mechanism was unknown. In order 
to begin assessing the mechanism, we tested other fundamental parameters of 
mitochondrial function, including MMP and ROS production. MMP is produced by 
pumping hydrogen ions across the inner mitochondrial membrane through the 
electron transport chain complexes. Loss of MMP may suggest mitochondrial 
uncoupling or that one or more of the ETC complexes is malfunctioning. Tzika et 
al. examined uncoupling in an in vivo model of cachexia and found ATP 
production was reduced by almost 50% (Tzika et al., 2013). We found that MMP 
was unaltered by any treatment, including LCM (Figure 4.4). These results were 
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expected as we have found that oxygen consumption is reduced in our model, 
suggesting a slowing of electron flow rather than uncoupling (McLean et al., 
2014). We have previously reported that ROS production is altered in our model, 
and therefore we examined whether COX-2 inhibition modified oxidant levels 
(McLean et al., 2014). 
 
4.4.4 COX-2 inhibition alters LCM-induced ROS 
Reactive oxygen species play an important role in maintenance and 
adaptation of skeletal muscle, and abnormal ROS production, such as seen in 
cachexia, may damage mitochondrial and myofibrillar proteins, and disrupt vital 
signaling pathways (Irrcher et al., 2009; Merry et al., 2010; Dutka et al., 2012; 
Luo et al., 2013; Michaelson et al., 2013; Prosser et al., 2013; McLean et al., 
2014). We have previously shown that production of reactive oxygen species 
(ROS) is initially elevated when myotubes are treated with LCM, but by 24hr after 
treatment, cytosolic oxidants are reduced compared to control levels, reflecting a 
reduction in electron transport chain activity (McLean et al., 2014). We tested the 
cytosolic oxidant level after 24hr of treatments by measuring DCFH fluorescence. 
LCM/NS-398 treatment showed DCFH fluorescence similar to control levels, 
while LCM alone was reduced (Figure 4.5A). We further tested mitochondrial 
oxidant production after 24hr using MitoSox fluorescence and found that no 
treatment altered mitochondrial oxidants compared to control (Figure 4.5B). 
These data confirm our previous results, which showed that LCM treatment 
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caused an initial rise in MitoSox fluorescence, but returned to basal levels 24hr 
after treatment.  
 
4.4.5 Conclusions 
Other studies have found that mitochondrial function is impaired in cachectic 
skeletal muscle, but no other study has examined how COX-2 inhibition affects 
mitochondrial function. Our novel results suggest that COX-2 inhibition may 
improve mitochondrial function in cachectic skeletal muscle, and may be the 
mechanism by which fatigue has been improved in clinical trials. Further studies 
are needed to elucidate the exact mechanism. 
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CHAPTER 5 
 
 
Final Discussion 
 
 
 
5.1 Tumor-derived factors induce loss of skeletal muscle mass  
 
Malignant tumors produce a variety of proteins. There is a consensus that 
cachexia is caused by multiple tumor- and host-derived factors, not all of which 
have been identified (Fearon et al., 2011; Tsoli and Robertson, 2013). Several 
well-known cachectic cytokines are elevated in cancer patients; however, clinical 
trials addressing them individually have proven ineffective (Barton, 2001; 
Jespersen et al., 2006; Kayacan et al., 2006; Gueta et al., 2010; White et al., 
2013; Lokireddy et al., 2015). These results suggest there may be as-of-yet 
unidentified agents of cachexia. In the first part of this thesis, our goal was to 
identify novel cachexia-inducing factors in lung cancer-conditioned media. 
 
5.1.1 Previously unidentified regulators of myosin 
There were 158 confirmed proteins in LCM (Appendix 2). After researching 
the functions of the secreted proteins (Appendix 3), we chose to examine the 14-
3-3 proteins, a family of proteins with numerous binding partners, and several 
mechanisms of regulating proteins. We believed that due to their signaling 
activity, they could potentially represent an unknown regulator of muscle mass 
(Freeman and Morrison, 2011; Gardino and Yaffe, 2011; Kleppe et al., 2011; 
Obsil, 2011). No other study has examined extracellular 14-3-3 proteins with 
regards to skeletal muscle.  
	  
 
	  
69 
We found that 14-3-3 content was depleted in LCM compared to C2C12 
myotube conditioned media. These results led us to examine the effect of 
neutralizing 14-3-3 proteins in cell culture media, which resulted in diminished 
myosin content. With no other muscle studies to which to compare our results, 
we chose to examine the proposed receptor for extracellular 14-3-3 proteins, 
CD13. 
 
5.1.2 CD13 receptor in skeletal muscle 
Immunofluorescence microscopy confirmed the presence of CD13 on 
differentiated myotubes, which is in itself a novel finding. We found that LCM 
treatment increased CD13 content in myotubes and that LCM contained elevated 
soluble CD13 content. CD13 is also elevated in tumors (Piedfer et al., 2011; 
Wickstrom et al., 2011). These results show that both tumors and cachectic 
muscle may act as sources of soluble CD13. We speculate that soluble CD13 
may bind 14-3-3 proteins in the same manner that soluble TNFα receptors 
capture TNFα: soluble CD13 may be the mechanism for depleting extracellular 
14-3-3. Our results using the inhibitor, Bestatin, suggest that CD13 (and perhaps 
other aminopeptidases) plays a role in regulating myosin content. On the other 
hand, the CD13 neutralizing antibody gave inconclusive results, but the 
experiment may have been statistically underpowered. 
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5.1.3 Conclusions and Future Directions 
Our goal in this study was to identify new cachexia-inducing proteins. Our 
findings show that: 1) extracellular 14-3-3 proteins appear to have a role in 
maintaining skeletal muscle mass, and some isoforms may act as previously 
unidentified myokines; 2) LCM increases CD13 content; and 3) soluble CD13 
may be the mechanism behind the decrease in 14-3-3 content in LCM (Figure 
5.1).  
Future studies should examine how individual extracellular 14-3-3 isoforms 
affect myosin content in myotubes as well as skeletal muscle mass. What role 
extracellular 14-3-3 proteins play in skeletal muscle is an unstudied area, which 
warrants attention. These proteins represent previously unknown regulators of 
muscle mass, and as such, they have the potential to impact overall health 
because it is known that loss of muscle mass is associated with an increase in 
morbidity and mortality. Other future studies should include examining 
differentiated skeletal muscle for the presence of CD13, determining its function 
in maintaining muscle mass in both the membrane-bound form and soluble form, 
and also examining what interaction soluble CD13 has with extracellular 14-3-3 
isoforms. 
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Figure 5.1 Model for depletion of 14-3-3 proteins by soluble CD13. A) 
Extracellular 14-3-3 proteins signal via CD13 in untreated skeletal muscle. B) In 
the presence of up-regulated soluble CD13 receptors, 14-3-3 proteins are bound 
in the extracellular space and cannot participate in homeostatic signaling. 
 
 
5.2 Mitochondrial dysfunction in cachexia 
Cachectic cancer patients frequently complain of fatigue, which may stem 
from mitochondrial dysfunction (Roberts et al., 2013a; Roberts et al., 2013b). 
Mitochondrial dysfunction has been reported in several models of cancer 
cachexia, including lung cancer-induced muscle wasting. Dysfunctional 
mitochondria can diminish ATP production and increase production of ROS, 
leading to less ATP for muscle contraction as well as free-radical damage to 
proteins, nucleic acids, and lipids. In the second part of this thesis, we used an in 
vitro model of cancer cachexia to focus on how cancer-conditioned media impact 
mitochondrial function. We found that LCM treatment alters mitochondrial oxygen 
consumption rate, ROS production, and induces oxidative stress. 
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In the third part of this thesis, we examined the effect of COX-2 inhibition 
on mitochondrial function in cachectic muscle. Clinical trials using COX-2 
inhibitors to treat cachexia have been some of the most successful to date. 
Although not entirely without side effects, COX-2 inhibitors are generally well 
tolerated. More importantly, they already have FDA approval, are inexpensive, 
and are anti-tumorigenic. COX-2 inhibition decreased fatigue in cachectic 
cancer patients, but no mechanism was identified (Baumgarten et al., 2007; 
Mantovani et al., 2010; Xu et al., 2015). The results suggest possible 
involvement of mitochondria because they are the main source of ATP. We 
found that COX-2 inhibition ameliorates some aspects of mitochondrial 
dysfunction in cachectic muscle. 
 
5.2.1 LCM treatment and COX-2 inhibition alter ETC activity 
We used the rate of mitochondrial oxygen consumption (OCR) as a way to 
measure ETC activity. LCM treatment altered ETC activity in C2C12 myotubes in 
a time-dependent manner. Although no other studies have used an XF Analyzer 
to examine cachectic myotubes, studies by Fontes-Oliveira et al. and 
Constantinou et al. found that ATP production was reduced in cachectic muscle 
(Constantinou et al., 2011; Fontes-Oliveira et al., 2013). In our follow-up study, 
we found that inhibiting COX-2 in LCM-treated myotubes increased OCR to 
control levels under all respiration conditions we tested. Our results indicate that 
cachexia-induced mitochondrial dysfunction may be alleviated by COX-2 
inhibition, although the mechanism remains unknown.  
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There are several mechanisms by which OCR may be diminished in LCM-
treated cells, and, accordingly, we tested mitochondrial quantity, the content of 
mitochondrial complexes, and ROS production. Neither mitochondrial quantity 
nor mitochondrial complexes content were altered by LCM treatment. However, 
we found that 2hrs of LCM treatment increased complex IV activity, which was 
unexpected. In reviewing the literature, we found that ETC-generated superoxide 
can reduce cytochrome c directly, which would increase complex IV activity in a 
manner that is separate from ATP production. These data indicated that ROS 
production was increased in our model.  
5.2.2 LCM treatment and COX-2 inhibition alter ROS 
ETC activity constitutively produces some ROS, which play an important 
role in maintenance and adaptation of skeletal muscle (St-Pierre et al., 2002; 
Turrens, 2003). However, abnormally high ROS production can damage 
mitochondrial and myofibrillar proteins. We hypothesized that LCM treatment 
induces excessive oxidant production. LCM initially increased cytosolic and 
mitochondrial oxidant production supporting our hypothesis, but by 24hr post-
treatment, cytosolic oxidant levels were less than control conditions. This 
decrease likely reflects a slowing of electron transport, which we hypothesized 
was due to damage to mitochondrial proteins caused the initial burst of ROS. 
When we performed similar experiments co-treating myotubes with LCM and a 
COX-2 inhibitor, cytosolic oxidants returned to levels similar to control. These 
studies support the idea that ROS contribute to cachexia-induced mitochondrial 
dysfunction. 
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5.2.3 LCM-treatment and uncoupling 
Some studies have suggested the ROS production is linked to an increase in 
mitochondrial uncoupling (Busquets et al., 2005; Russell et al., 2007). 
Uncoupling may increase in response to elevated ROS production as a means of 
reducing ROS and the potential damage they inflict (MacLellan et al., 2005; 
Toime and Brand, 2010). Although our OCR findings did not suggest uncoupling, 
we felt that the results from other studies warranted these experiments.  
Other studies on cachectic skeletal muscle have found both increased and 
unchanged expression of uncoupling protein three (UCP3), the main uncoupling 
protein in skeletal muscle (Vidal-Puig et al., 1997; Constantinou et al., 2011; 
Julienne et al., 2012; Antunes et al., 2014). We tested the mitochondrial 
membrane potential (MMP) and UCP3 content. MMP is generated when the 
electron transport chain complexes pump hydrogen ions across the inner 
mitochondrial membrane. Loss of MMP may suggest mitochondrial uncoupling. 
We found that MMP was unaltered by any treatment, including LCM and COX-2 
inhibition. These results were expected as we have found that oxygen 
consumption is reduced in our model, suggesting a slowing of electron flow 
rather than uncoupling. We also found no change in the expression of UCP3 
despite the depression in ROS production.  
With UCP3 and MMP unchanged, we hypothesized that the initial rise in 
oxidants with LCM treatment caused oxidative damage to mitochondrial proteins, 
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decreased ETC activity because of this damage, and ultimately lead to the 
subsequent decrease in ETC-generated ROS production over time. 
 
5.3.4 LCM-treatment increases oxidative damage 
4-hydroxynonenal is a product of lipid peroxidation, and acts as both a marker 
and inducer of oxidative stress. It is known to aggregate and cause oxidative 
damage to DNA, lipids, and proteins (Chen and Niki, 2006). Western blot for 
4HNE-modified proteins in cytosolic and mitochondrial fractions of myotube 
lysates showed that LCM treatment increased oxidative damage. These data  
supported our hypothesis that LCM induces an initial rise in oxidants, which 
damage mitochondrial proteins and lead to depressed ETC activity. 
 
5.3.5 Conclusions and future directions 
 Our results show that myotubes treated with LCM experience altered ETC 
activity, including reduced basal respiration and ATP-related OCR as well as an 
initial burst of ROS production, some of which is mitochondrial superoxide 
(Figure 5.2). We confirmed that LCM induces oxidative damage to proteins, and 
potentially creates a self-amplifying loop of oxidative stress.  
Future work should focus on finding therapeutics to alleviate mitochondrial 
stress in cachectic skeletal muscle under the condition that such therapeutics do 
not positively affect tumor growth. With this consideration in mind, further studies 
are needed to delineate how COX-2 inhibition alters mitochondrial function in 
cachectic muscle because COX-2 inhibition is already known to be anti-
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tumorigenic. COX-2 inhibition potentially represents a safe and readily available 
means of treating fatigue in cachectic cancer patients. Future studies should also 
include investigating whether extracellular 14-3-3 proteins affect mitochondrial 
function in myotubes, which is an entirely unknown area of study. If so, then 
extracellular 14-3-3 proteins may be an important regular of muscle mass and 
fatigue in diseased states.  
 
 
Figure 5.2 Model of lung cancer-induced mitochondrial dysfunction. LCM 
induces an increase in oxidant production, an increase in oxidative damage, and 
a decrease in ETC activity. 
 
 
5.3 Final conclusions 
 
In the clinical setting, addressing cachexia is generally overlooked by 
physicians, who hold the belief that treating the tumor treats the cachexia. While 
true, this limited approach underestimates the role of skeletal muscle not only in 
quality of life, but also its recently discovered endocrine role, the implications of 
which are still being investigated. Muscle wasting is thought to contribute directly 
to 30% of all cancer deaths, but we still do not know exactly how cachexia kills 
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(Fox and Wang, 2007; Fearon, 2008; Tisdale, 2009; Kalantar-Zadeh et al., 2013). 
It stands to reason that addressing cachexia will save lives.  
The primary goal of this thesis was to investigate under-studied aspects of 
cancer cachexia that could contribute to the development of therapeutics for 
treating muscle wasting and fatigue. The research paths used to obtain this goal 
were: 1) to identify novel tumor-derived candidates that contribute to cachexia; 
and 2) to assess cancer-induced mitochondrial dysfunction and its possible 
contribution to fatigue. We executed these studies using an in vitro model of lung 
cancer-induced cachexia that have revealed previously unknown contributors to, 
and aspects of, muscle wasting. Our findings showed that extracellular 14-3-3 
proteins may act as previously unidentified myokines, and that their depletion 
may contribute to muscle wasting. CD13 may act as the means of depleting 
extracellular 14-3-3 proteins, and, if so, it could be a target for therapeutic 
intervention. Whether extracellular 14-3-3 proteins affect mitochondrial function is 
currently unknown. If they do, they may be a link between myosin loss and 
mitochondrial dysfunction. Further studies may also examine the effect of COX-2 
inhibition on extracellular 14-3-3 proteins and vice versa, another potential 
networking of myosin loss and mitochondrial dysfunction. 
Cancer cachexia is a complex syndrome with multiple contributing factors 
and signaling pathways. Increasing our knowledge of the intricacies involved in 
muscle wasting and fatigue will help point the way to developing treatments. In 
conclusion, our findings have uncovered previously unknown factors and 
relationships that will inform therapeutic discovery. 
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APPENDICES	  
	  
	  
	  
Appendix	  1.	  Abbreviations	  
	  
	  
ATP  Adenosine Triphosphate 
CI  Mitochondrial Complex I 
CIII  Mitochondrial Complex III 
CIV   Mitochondrial Complex IV 
DAF  4,5-Diaminofluorescein diacetate 
DCFH  Dichloro-dihydro-fluorescein diacetate 
DNA  Deoxyribonucleic acid 
ETC  Electron Transport Chain 
FADH  Flavin adenine dinucleotide 
4HNE  4-Hydroxynonenal 
LCM  Lewis lung carcinoma condition media 
NADH  Nicotinamide adenine dinucleotide 
OCR  Oxygen consumption rate 
ROS  Reactive oxygen species 
SDS   Sodium dodecyl sulfate 
PAGE  Polyacrylamide gel electrophoresis 
VDAC  Voltage dependent anion channel 
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Appendix 2. Mass Spectrometry results of confirmed LCM contents 
Accession Protein name 
P62259 14-3-3 protein epsilon OS=Mus musculus GN=Ywhae PE=1 SV=1 - [1433E_MOUSE] 
P68510 14-3-3 protein eta OS=Mus musculus GN=Ywhah PE=1 SV=2 - [1433F_MOUSE] 
P61982 14-3-3 protein gamma OS=Mus musculus GN=Ywhag PE=1 SV=2 - [1433G_MOUSE] 
O70456 14-3-3 protein sigma OS=Mus musculus GN=Sfn PE=1 SV=1 - [1433S_MOUSE] 
P68254 14-3-3 protein theta OS=Mus musculus GN=Ywhaq PE=1 SV=1 - [1433T_MOUSE] 
P63101 14-3-3 protein zeta/delta OS=Mus musculus GN=Ywhaz PE=1 SV=1 - [1433Z_MOUSE] 
Q9DCD0 6-phosphogluconate dehydrogenase, decarboxylating OS=Mus musculus GN=Pgd PE=2 SV=3 - 
[6PGD_MOUSE] 
P47955 60S acidic ribosomal protein P1 OS=Mus musculus GN=Rplp1 PE=1 SV=1 - [RLA1_MOUSE] 
P68033 Actin, alpha cardiac muscle 1 OS=Mus musculus GN=Actc1 PE=1 SV=1 - [ACTC_MOUSE] 
P68134 Actin, alpha skeletal muscle OS=Mus musculus GN=Acta1 PE=1 SV=1 - [ACTS_MOUSE] 
P62737 Actin, aortic smooth muscle OS=Mus musculus GN=Acta2 PE=1 SV=1 - [ACTA_MOUSE] 
P60710 Actin, cytoplasmic 1 OS=Mus musculus GN=Actb PE=1 SV=1 - [ACTB_MOUSE] 
P63260 Actin, cytoplasmic 2 OS=Mus musculus GN=Actg1 PE=1 SV=1 - [ACTG_MOUSE] 
P63268 Actin, gamma-enteric smooth muscle OS=Mus musculus GN=Actg2 PE=2 SV=1 - [ACTH_MOUSE] 
Q640N1 Adipocyte enhancer-binding protein 1 OS=Mus musculus GN=Aebp1 PE=1 SV=1 - [AEBP1_MOUSE] 
P45376 Aldose reductase OS=Mus musculus GN=Akr1b1 PE=1 SV=3 - [ALDR_MOUSE] 
Q7TPR4 Alpha-actinin-1 OS=Mus musculus GN=Actn1 PE=2 SV=1 - [ACTN1_MOUSE] 
P57780 Alpha-actinin-4 OS=Mus musculus GN=Actn4 PE=1 SV=1 - [ACTN4_MOUSE] 
P17182 Alpha-enolase OS=Mus musculus GN=Eno1 PE=1 SV=3 - [ENOA_MOUSE] 
P10107 Annexin A1 OS=Mus musculus GN=Anxa1 PE=1 SV=2 - [ANXA1_MOUSE] 
P07356 Annexin A2 OS=Mus musculus GN=Anxa2 PE=1 SV=2 - [ANXA2_MOUSE] 
P48036 Annexin A5 OS=Mus musculus GN=Anxa5 PE=1 SV=1 - [ANXA5_MOUSE] 
Q05793 Basement membrane-specific heparan sulfate proteoglycan core protein OS=Mus musculus GN=Hspg2 
PE=1 SV=1 - [PGBM_MOUSE] 
Q8BFZ3 Beta-actin-like protein 2 OS=Mus musculus GN=Actbl2 PE=1 SV=1 - [ACTBL_MOUSE] 
P21550 Beta-enolase OS=Mus musculus GN=Eno3 PE=1 SV=3 - [ENOB_MOUSE] 
P28653 Biglycan OS=Mus musculus GN=Bgn PE=2 SV=1 - [PGS1_MOUSE] 
Q00493 Carboxypeptidase E OS=Mus musculus GN=Cpe PE=1 SV=2 - [CBPE_MOUSE] 
P10605 Cathepsin B OS=Mus musculus GN=Ctsb PE=1 SV=2 - [CATB_MOUSE] 
P06797 Cathepsin L1 OS=Mus musculus GN=Ctsl1 PE=1 SV=2 - [CATL1_MOUSE] 
Q9Z1Q5 Chloride intracellular channel protein 1 OS=Mus musculus GN=Clic1 PE=1 SV=3 - [CLIC1_MOUSE] 
Q06890 Clusterin OS=Mus musculus GN=Clu PE=1 SV=1 - [CLUS_MOUSE] 
P18760 Cofilin-1 OS=Mus musculus GN=Cfl1 PE=1 SV=3 - [COF1_MOUSE] 
P45591 Cofilin-2 OS=Mus musculus GN=Cfl2 PE=1 SV=1 - [COF2_MOUSE] 
Q8CDN8 Coiled-coil domain-containing protein 38 OS=Mus musculus GN=Ccdc38 PE=2 SV=1 - [CCD38_MOUSE] 
Q9D9C6 Coiled-coil domain-containing protein ENSP00000299415 homolog OS=Mus musculus PE=2 SV=1 - 
[YQ013_MOUSE] 
P08121 Collagen alpha-1(III) chain OS=Mus musculus GN=Col3a1 PE=2 SV=4 - [CO3A1_MOUSE] 
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O88207 Collagen alpha-1(V) chain OS=Mus musculus GN=Col5a1 PE=2 SV=2 - [CO5A1_MOUSE] 
P39061 Collagen alpha-1(XVIII) chain OS=Mus musculus GN=Col18a1 PE=1 SV=4 - [COIA1_MOUSE] 
P21460 Cystatin-C OS=Mus musculus GN=Cst3 PE=2 SV=2 - [CYTC_MOUSE] 
Q62165 Dystroglycan OS=Mus musculus GN=Dag1 PE=1 SV=4 - [DAG1_MOUSE] 
P10126 Elongation factor 1-alpha 1 OS=Mus musculus GN=Eef1a1 PE=1 SV=3 - [EF1A1_MOUSE] 
P62631 Elongation factor 1-alpha 2 OS=Mus musculus GN=Eef1a2 PE=1 SV=1 - [EF1A2_MOUSE] 
O70251 Elongation factor 1-beta OS=Mus musculus GN=Eef1b PE=1 SV=5 - [EF1B_MOUSE] 
P58252 Elongation factor 2 OS=Mus musculus GN=Eef2 PE=1 SV=2 - [EF2_MOUSE] 
P26040 Ezrin OS=Mus musculus GN=Ezr PE=1 SV=3 - [EZRI_MOUSE] 
P11276 Fibronectin OS=Mus musculus GN=Fn1 PE=1 SV=3 - [FINC_MOUSE] 
P05064 Fructose-bisphosphate aldolase A OS=Mus musculus GN=Aldoa PE=1 SV=2 - [ALDOA_MOUSE] 
P16045 Galectin-1 OS=Mus musculus GN=Lgals1 PE=1 SV=3 - [LEG1_MOUSE] 
P17183 Gamma-enolase OS=Mus musculus GN=Eno2 PE=1 SV=2 - [ENOG_MOUSE] 
P13020 Gelsolin OS=Mus musculus GN=Gsn PE=1 SV=3 - [GELS_MOUSE] 
O09131 Glutathione S-transferase omega-1 OS=Mus musculus GN=Gsto1 PE=2 SV=2 - [GSTO1_MOUSE] 
P16858 Glyceraldehyde-3-phosphate dehydrogenase OS=Mus musculus GN=Gapdh PE=1 SV=2 - [G3P_MOUSE] 
Q64467 Glyceraldehyde-3-phosphate dehydrogenase, testis-specific OS=Mus musculus GN=Gapdhs PE=1 SV=1 - 
[G3PT_MOUSE] 
Q9QZF2 Glypican-1 OS=Mus musculus GN=Gpc1 PE=1 SV=1 - [GPC1_MOUSE] 
P16627 Heat shock 70 kDa protein 1-like OS=Mus musculus GN=Hspa1l PE=2 SV=4 - [HS71L_MOUSE] 
Q8BM72 Heat shock 70 kDa protein 13 OS=Mus musculus GN=Hspa13 PE=2 SV=1 - [HSP13_MOUSE] 
Q61696 Heat shock 70 kDa protein 1A OS=Mus musculus GN=Hspa1a PE=1 SV=2 - [HS71A_MOUSE] 
P17879 Heat shock 70 kDa protein 1B OS=Mus musculus GN=Hspa1b PE=1 SV=3 - [HS71B_MOUSE] 
P63017 Heat shock cognate 71 kDa protein OS=Mus musculus GN=Hspa8 PE=1 SV=1 - [HSP7C_MOUSE] 
P07901 Heat shock protein HSP 90-alpha OS=Mus musculus GN=Hsp90aa1 PE=1 SV=4 - [HS90A_MOUSE] 
P11499 Heat shock protein HSP 90-beta OS=Mus musculus GN=Hsp90ab1 PE=1 SV=2 - [HS90B_MOUSE] 
P17156 Heat shock-related 70 kDa protein 2 OS=Mus musculus GN=Hspa2 PE=1 SV=1 - [HSP72_MOUSE] 
Q9Z2X1 Heterogeneous nuclear ribonucleoprotein F OS=Mus musculus GN=Hnrnpf PE=1 SV=3 - [HNRPF_MOUSE] 
O88569 Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Mus musculus GN=Hnrnpa2b1 PE=1 SV=2 - 
[ROA2_MOUSE] 
P22752 Histone H2A type 1 OS=Mus musculus GN=Hist1h2ab PE=1 SV=3 - [H2A1_MOUSE] 
Q8CGP5 Histone H2A type 1-F OS=Mus musculus GN=Hist1h2af PE=1 SV=3 - [H2A1F_MOUSE] 
Q8CGP6 Histone H2A type 1-H OS=Mus musculus GN=Hist1h2ah PE=1 SV=3 - [H2A1H_MOUSE] 
Q8CGP7 Histone H2A type 1-K OS=Mus musculus GN=Hist1h2ak PE=1 SV=3 - [H2A1K_MOUSE] 
Q6GSS7 Histone H2A type 2-A OS=Mus musculus GN=Hist2h2aa1 PE=1 SV=3 - [H2A2A_MOUSE] 
Q64523 Histone H2A type 2-C OS=Mus musculus GN=Hist2h2ac PE=1 SV=3 - [H2A2C_MOUSE] 
Q8BFU2 Histone H2A type 3 OS=Mus musculus GN=Hist3h2a PE=1 SV=3 - [H2A3_MOUSE] 
Q8R1M2 Histone H2A.J OS=Mus musculus GN=H2afj PE=2 SV=1 - [H2AJ_MOUSE] 
P70168 Importin subunit beta-1 OS=Mus musculus GN=Kpnb1 PE=1 SV=1 - [IMB1_MOUSE] 
P47879 Insulin-like growth factor-binding protein 4 OS=Mus musculus GN=Igfbp4 PE=2 SV=2 - [IBP4_MOUSE] 
O89051 Integral membrane protein 2B OS=Mus musculus GN=Itm2b PE=2 SV=1 - [ITM2B_MOUSE] 
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P02535 Keratin, type I cytoskeletal 10 OS=Mus musculus GN=Krt10 PE=1 SV=3 - [K1C10_MOUSE] 
P04104 Keratin, type II cytoskeletal 1 OS=Mus musculus GN=Krt1 PE=1 SV=4 - [K2C1_MOUSE] 
Q6IFZ6 Keratin, type II cytoskeletal 1b OS=Mus musculus GN=Krt77 PE=1 SV=1 - [K2C1B_MOUSE] 
Q922U2 Keratin, type II cytoskeletal 5 OS=Mus musculus GN=Krt5 PE=1 SV=1 - [K2C5_MOUSE] 
P50446 Keratin, type II cytoskeletal 6A OS=Mus musculus GN=Krt6a PE=2 SV=3 - [K2C6A_MOUSE] 
Q9Z331 Keratin, type II cytoskeletal 6B OS=Mus musculus GN=Krt6b PE=1 SV=3 - [K2C6B_MOUSE] 
Q9R0H5 Keratin, type II cytoskeletal 71 OS=Mus musculus GN=Krt71 PE=1 SV=1 - [K2C71_MOUSE] 
Q6NXH9 Keratin, type II cytoskeletal 73 OS=Mus musculus GN=Krt73 PE=1 SV=1 - [K2C73_MOUSE] 
Q6IFZ9 Keratin, type II cytoskeletal 74 OS=Mus musculus GN=Krt74 PE=2 SV=1 - [K2C74_MOUSE] 
Q8BGZ7 Keratin, type II cytoskeletal 75 OS=Mus musculus GN=Krt75 PE=1 SV=1 - [K2C75_MOUSE] 
Q8VED5 Keratin, type II cytoskeletal 79 OS=Mus musculus GN=Krt79 PE=1 SV=2 - [K2C79_MOUSE] 
P06151 L-lactate dehydrogenase A chain OS=Mus musculus GN=Ldha PE=1 SV=3 - [LDHA_MOUSE] 
P00342 L-lactate dehydrogenase C chain OS=Mus musculus GN=Ldhc PE=1 SV=2 - [LDHC_MOUSE] 
P02469 Laminin subunit beta-1 OS=Mus musculus GN=Lamb1-1 PE=1 SV=2 - [LAMB1_MOUSE] 
P02468 Laminin subunit gamma-1 OS=Mus musculus GN=Lamc1 PE=1 SV=2 - [LAMC1_MOUSE] 
Q8CG19 Latent-transforming growth factor beta-binding protein 1 OS=Mus musculus GN=Ltbp1 PE=2 SV=2 - 
[LTBP1_MOUSE] 
P34884 Macrophage migration inhibitory factor OS=Mus musculus GN=Mif PE=1 SV=2 - [MIF_MOUSE] 
P26041 Moesin OS=Mus musculus GN=Msn PE=1 SV=3 - [MOES_MOUSE] 
Q9Z2L6 Multiple inositol polyphosphate phosphatase 1 OS=Mus musculus GN=Minpp1 PE=1 SV=2 - 
[MINP1_MOUSE] 
Q69ZN7 Myoferlin OS=Mus musculus GN=Myof PE=1 SV=2 - [MYOF_MOUSE] 
O08638 Myosin-11 OS=Mus musculus GN=Myh11 PE=1 SV=1 - [MYH11_MOUSE] 
Q6URW6 Myosin-14 OS=Mus musculus GN=Myh14 PE=1 SV=1 - [MYH14_MOUSE] 
Q8VDD5 Myosin-9 OS=Mus musculus GN=Myh9 PE=1 SV=4 - [MYH9_MOUSE] 
Q99J85 Neuronal pentraxin receptor OS=Mus musculus GN=Nptxr PE=2 SV=1 - [NPTXR_MOUSE] 
Q62443 Neuronal pentraxin-1 OS=Mus musculus GN=Nptx1 PE=2 SV=1 - [NPTX1_MOUSE] 
Q8BHN3 Neutral alpha-glucosidase AB OS=Mus musculus GN=Ganab PE=1 SV=1 - [GANAB_MOUSE] 
P10493 Nidogen-1 OS=Mus musculus GN=Nid1 PE=1 SV=1 - [NID1_MOUSE] 
O88322 Nidogen-2 OS=Mus musculus GN=Nid2 PE=1 SV=1 - [NID2_MOUSE] 
Q02819 Nucleobindin-1 OS=Mus musculus GN=Nucb1 PE=1 SV=2 - [NUCB1_MOUSE] 
P09405 Nucleolin OS=Mus musculus GN=Ncl PE=1 SV=2 - [NUCL_MOUSE] 
P17742 Peptidyl-prolyl cis-trans isomerase A OS=Mus musculus GN=Ppia PE=1 SV=2 - [PPIA_MOUSE] 
P24369 Peptidyl-prolyl cis-trans isomerase B OS=Mus musculus GN=Ppib PE=2 SV=2 - [PPIB_MOUSE] 
P30412 Peptidyl-prolyl cis-trans isomerase C OS=Mus musculus GN=Ppic PE=1 SV=1 - [PPIC_MOUSE] 
P15331 Peripherin OS=Mus musculus GN=Prph PE=1 SV=2 - [PERI_MOUSE] 
Q3UQ28 Peroxidasin homolog OS=Mus musculus GN=Pxdn PE=2 SV=1 - [PXDN_MOUSE] 
P35700 Peroxiredoxin-1 OS=Mus musculus GN=Prdx1 PE=1 SV=1 - [PRDX1_MOUSE] 
O08807 Peroxiredoxin-4 OS=Mus musculus GN=Prdx4 PE=1 SV=1 - [PRDX4_MOUSE] 
O08709 Peroxiredoxin-6 OS=Mus musculus GN=Prdx6 PE=1 SV=3 - [PRDX6_MOUSE] 
P70296 Phosphatidylethanolamine-binding protein 1 OS=Mus musculus GN=Pebp1 PE=1 SV=3 - [PEBP1_MOUSE] 
	  
 
	  
82 
P09411 Phosphoglycerate kinase 1 OS=Mus musculus GN=Pgk1 PE=1 SV=4 - [PGK1_MOUSE] 
Q9DBJ1 Phosphoglycerate mutase 1 OS=Mus musculus GN=Pgam1 PE=1 SV=3 - [PGAM1_MOUSE] 
P97298 Pigment epithelium-derived factor OS=Mus musculus GN=Serpinf1 PE=1 SV=2 - [PEDF_MOUSE] 
Q60963 Platelet-activating factor acetylhydrolase OS=Mus musculus GN=Pla2g7 PE=2 SV=2 - [PAFA_MOUSE] 
P0CG49 Polyubiquitin-B OS=Mus musculus GN=Ubb PE=1 SV=1 - [UBB_MOUSE] 
P0CG50 Polyubiquitin-C OS=Mus musculus GN=Ubc PE=1 SV=1 - [UBC_MOUSE] 
Q61398 Procollagen C-endopeptidase enhancer 1 OS=Mus musculus GN=Pcolce PE=1 SV=2 - [PCOC1_MOUSE] 
P62962 Profilin-1 OS=Mus musculus GN=Pfn1 PE=1 SV=2 - [PROF1_MOUSE] 
P27773 Protein disulfide-isomerase A3 OS=Mus musculus GN=Pdia3 PE=1 SV=2 - [PDIA3_MOUSE] 
Q922R8 Protein disulfide-isomerase A6 OS=Mus musculus GN=Pdia6 PE=1 SV=3 - [PDIA6_MOUSE] 
P09103 Protein disulfide-isomerase OS=Mus musculus GN=P4hb PE=1 SV=1 - [PDIA1_MOUSE] 
P52480 Pyruvate kinase isozymes M1/M2 OS=Mus musculus GN=Pkm2 PE=1 SV=4 - [KPYM_MOUSE] 
P53657 Pyruvate kinase isozymes R/L OS=Mus musculus GN=Pklr PE=2 SV=1 - [KPYR_MOUSE] 
Q61598 Rab GDP dissociation inhibitor beta OS=Mus musculus GN=Gdi2 PE=1 SV=1 - [GDIB_MOUSE] 
P26043 Radixin OS=Mus musculus GN=Rdx PE=1 SV=2 - [RADI_MOUSE] 
P07214 SPARC OS=Mus musculus GN=Sparc PE=1 SV=1 - [SPRC_MOUSE] 
P28862 Stromelysin-1 OS=Mus musculus GN=Mmp3 PE=2 SV=2 - [MMP3_MOUSE] 
O55123 Stromelysin-2 OS=Mus musculus GN=Mmp10 PE=2 SV=1 - [MMP10_MOUSE] 
Q8BND5 Sulfhydryl oxidase 1 OS=Mus musculus GN=Qsox1 PE=2 SV=1 - [QSOX1_MOUSE] 
Q03350 Thrombospondin-2 OS=Mus musculus GN=Thbs2 PE=2 SV=1 - [TSP2_MOUSE] 
P17751 Triosephosphate isomerase OS=Mus musculus GN=Tpi1 PE=1 SV=3 - [TPIS_MOUSE] 
P68369 Tubulin alpha-1A chain OS=Mus musculus GN=Tuba1a PE=1 SV=1 - [TBA1A_MOUSE] 
P05213 Tubulin alpha-1B chain OS=Mus musculus GN=Tuba1b PE=1 SV=2 - [TBA1B_MOUSE] 
P68373 Tubulin alpha-1C chain OS=Mus musculus GN=Tuba1c PE=1 SV=1 - [TBA1C_MOUSE] 
P05214 Tubulin alpha-3 chain OS=Mus musculus GN=Tuba3a PE=1 SV=1 - [TBA3_MOUSE] 
P68368 Tubulin alpha-4A chain OS=Mus musculus GN=Tuba4a PE=1 SV=1 - [TBA4A_MOUSE] 
Q9JJZ2 Tubulin alpha-8 chain OS=Mus musculus GN=Tuba8 PE=1 SV=1 - [TBA8_MOUSE] 
Q7TMM9 Tubulin beta-2A chain OS=Mus musculus GN=Tubb2a PE=1 SV=1 - [TBB2A_MOUSE] 
Q9CWF2 Tubulin beta-2B chain OS=Mus musculus GN=Tubb2b PE=1 SV=1 - [TBB2B_MOUSE] 
P68372 Tubulin beta-2C chain OS=Mus musculus GN=Tubb2c PE=1 SV=1 - [TBB2C_MOUSE] 
Q9ERD7 Tubulin beta-3 chain OS=Mus musculus GN=Tubb3 PE=1 SV=1 - [TBB3_MOUSE] 
Q9D6F9 Tubulin beta-4 chain OS=Mus musculus GN=Tubb4 PE=1 SV=3 - [TBB4_MOUSE] 
P99024 Tubulin beta-5 chain OS=Mus musculus GN=Tubb5 PE=1 SV=1 - [TBB5_MOUSE] 
Q922F4 Tubulin beta-6 chain OS=Mus musculus GN=Tubb6 PE=1 SV=1 - [TBB6_MOUSE] 
P62983 Ubiquitin-40S ribosomal protein S27a OS=Mus musculus GN=Rps27a PE=1 SV=2 - [RS27A_MOUSE] 
P62984 Ubiquitin-60S ribosomal protein L40 OS=Mus musculus GN=Uba52 PE=1 SV=2 - [RL40_MOUSE] 
P06869 Urokinase-type plasminogen activator OS=Mus musculus GN=Plau PE=1 SV=1 - [UROK_MOUSE] 
Q9R1Q9 V-type proton ATPase subunit S1 OS=Mus musculus GN=Atp6ap1 PE=1 SV=1 - [VAS1_MOUSE] 
Q62059 Versican core protein OS=Mus musculus GN=Vcan PE=1 SV=2 - [CSPG2_MOUSE] 
P20152 Vimentin OS=Mus musculus GN=Vim PE=1 SV=3 - [VIME_MOUSE] 
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Appendix 3. Secreted proteins found in LCM 
Accession Protein name 
P62259 14-3-3 protein epsilon OS=Mus musculus GN=Ywhae PE=1 SV=1 - [1433E_MOUSE] 
P68510 14-3-3 protein eta OS=Mus musculus GN=Ywhah PE=1 SV=2 - [1433F_MOUSE] 
P61982 14-3-3 protein gamma OS=Mus musculus GN=Ywhag PE=1 SV=2 - [1433G_MOUSE] 
O70456 14-3-3 protein sigma OS=Mus musculus GN=Sfn PE=1 SV=1 - [1433S_MOUSE] 
P68254 14-3-3 protein theta OS=Mus musculus GN=Ywhaq PE=1 SV=1 - [1433T_MOUSE] 
P63101 14-3-3 protein zeta/delta OS=Mus musculus GN=Ywhaz PE=1 SV=1 - [1433Z_MOUSE] 
Q640N1 Adipocyte enhancer-binding protein 1 OS=Mus musculus GN=Aebp1 PE=1 SV=1 - [AEBP1_MOUSE] 
P07356 Annexin A2 OS=Mus musculus GN=Anxa2 PE=1 SV=2 - [ANXA2_MOUSE] 
Q05793 Basement membrane-specific heparan sulfate proteoglycan core protein OS=Mus musculus GN=Hspg2 PE=1 SV=1 - [PGBM_MOUSE] 
Q8BFZ3 Beta-actin-like protein 2 OS=Mus musculus GN=Actbl2 PE=1 SV=1 - [ACTBL_MOUSE] 
P21550 Beta-enolase OS=Mus musculus GN=Eno3 PE=1 SV=3 - [ENOB_MOUSE] 
P28653 Biglycan OS=Mus musculus GN=Bgn PE=2 SV=1 - [PGS1_MOUSE] 
Q00493 Carboxypeptidase E OS=Mus musculus GN=Cpe PE=1 SV=2 - [CBPE_MOUSE] 
P10605 Cathepsin B OS=Mus musculus GN=Ctsb PE=1 SV=2 - [CATB_MOUSE] 
P08121 Collagen alpha-1(III) chain OS=Mus musculus GN=Col3a1 PE=2 SV=4 - [CO3A1_MOUSE] 
P39061 Collagen alpha-1(XVIII) chain OS=Mus musculus GN=Col18a1 PE=1 SV=4 - [COIA1_MOUSE] 
P21460 Cystatin-C OS=Mus musculus GN=Cst3 PE=2 SV=2 - [CYTC_MOUSE] 
Q62165 Dystroglycan OS=Mus musculus GN=Dag1 PE=1 SV=4 - [DAG1_MOUSE] 
P11276 Fibronectin OS=Mus musculus GN=Fn1 PE=1 SV=3 - [FINC_MOUSE] 
P16045 Galectin-1 OS=Mus musculus GN=Lgals1 PE=1 SV=3 - [LEG1_MOUSE] 
P47879 Insulin-like growth factor-binding protein 4 OS=Mus musculus GN=Igfbp4 PE=2 SV=2 - [IBP4_MOUSE] 
P02468 Laminin subunit gamma-1 OS=Mus musculus GN=Lamc1 PE=1 SV=2 - [LAMC1_MOUSE] 
Q8CG19 Latent-transforming growth factor beta-binding protein 1 OS=Mus musculus GN=Ltbp1 PE=2 SV=2 - [LTBP1_MOUSE] 
P34884 Macrophage migration inhibitory factor OS=Mus musculus GN=Mif PE=1 SV=2 - [MIF_MOUSE] 
P10493 Nidogen-1 OS=Mus musculus GN=Nid1 PE=1 SV=1 - [NID1_MOUSE] 
P17742 Peptidyl-prolyl cis-trans isomerase A OS=Mus musculus GN=Ppia PE=1 SV=2 - [PPIA_MOUSE] 
O08807 Peroxiredoxin-4 OS=Mus musculus GN=Prdx4 PE=1 SV=1 - [PRDX4_MOUSE] 
P97298 Pigment epithelium-derived factor OS=Mus musculus GN=Serpinf1 PE=1 SV=2 - [PEDF_MOUSE] 
Q60963 Platelet-activating factor acetylhydrolase OS=Mus musculus GN=Pla2g7 PE=2 SV=2 - [PAFA_MOUSE] 
P07214 SPARC OS=Mus musculus GN=Sparc PE=1 SV=1 - [SPRC_MOUSE] 
O55123 Stromelysin-2 OS=Mus musculus GN=Mmp10 PE=2 SV=1 - [MMP10_MOUSE] 
Q03350 Thrombospondin-2 OS=Mus musculus GN=Thbs2 PE=2 SV=1 - [TSP2_MOUSE] 
Q62059 Versican core protein OS=Mus musculus GN=Vcan PE=1 SV=2 - [CSPG2_MOUSE] 
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